Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1
value | Author stringclasses 1
value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
38400.0 | 2019-05-27 00:00:00 UTC | Forget Aurora Cannabis: These 3 Growers Offer a More Attractive Value Proposition | ACB | https://www.nasdaq.com/articles/forget-aurora-cannabis%3A-these-3-growers-offer-more-attractive-value-proposition-2019-05-27 | nan | nan | Chances are that you'd struggle to find a faster-growing industry right now than legal marijuana. With global sales expected to grow by 38% in 2019, and more than double between 2018 and 2022, the cannabis industry has all the makings of a once-in-a-generation investment opportunity.
Then again, choosing what stocks to... | Marijuana stock Aurora Cannabis has gained quite the following Among millennials, there's no marijuana stock more popular than Aurora Cannabis (NYSE: ACB). A recently announced expansion at its flagship Aurora Sun campus in Medicine Hat, Alberta, to 1.62 million square feet will see a minimum of 230,000 kilos produced ... | Marijuana stock Aurora Cannabis has gained quite the following Among millennials, there's no marijuana stock more popular than Aurora Cannabis (NYSE: ACB). That's better than 140 grams per square foot, or 40% higher than the industry average of closer to 100 grams per square foot of dried flower yield. At the company's... | Marijuana stock Aurora Cannabis has gained quite the following Among millennials, there's no marijuana stock more popular than Aurora Cannabis (NYSE: ACB). Forget Aurora Cannabis: There are better pot stocks to consider buying But it's also a company that's heavily reliant on inorganic growth, and it finances these acq... | Marijuana stock Aurora Cannabis has gained quite the following Among millennials, there's no marijuana stock more popular than Aurora Cannabis (NYSE: ACB). Based in New Brunswick, OrganiGram is the only major grower in an Eastern Canadian province (by "major," I'm talking about more than 100,000 kilos a year projected ... |
38401.0 | 2019-05-26 00:00:00 UTC | Which Smaller Marijuana Stock Is Most Likely to Join Aurora Cannabis and Canopy Growth at the Top? | ACB | https://www.nasdaq.com/articles/which-smaller-marijuana-stock-most-likely-join-aurora-cannabis-and-canopy-growth-top-2019 | nan | nan | Let's face it: Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) are pretty much in a league of their own among marijuana stocks. They have the biggest market caps, the highest production capacities, and the most significant international operations.
Which smaller Canadian marijuana stock has the best shot at j... | Let's face it: Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) are pretty much in a league of their own among marijuana stocks. But the company's low production costs, industry-leading gross margins, and overall potential could catch the attention of some major players in the alcoholic beverages, consumer pac... | Let's face it: Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) are pretty much in a league of their own among marijuana stocks. Which smaller Canadian marijuana stock has the best shot at joining the ranks with these top-tier players? HEXO is sort of the oddball of the three smaller marijuana stocks that coul... | Let's face it: Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) are pretty much in a league of their own among marijuana stocks. Organigram Organigram is beating Aurora, Canopy Growth, and nearly every other Canadian marijuana stock in one key arena -- stock performance. HEXO is sort of the oddball of the thre... | Let's face it: Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) are pretty much in a league of their own among marijuana stocks. Like Aphria, Organigram doesn't have a big partner outside of the cannabis industry. The deal gives the company a market share of at least 30% for the next few years. |
38402.0 | 2019-05-25 00:00:00 UTC | Canada's Marijuana Sales Hit a Record High in March, but That's Not Saying Much | ACB | https://www.nasdaq.com/articles/canadas-marijuana-sales-hit-record-high-march-thats-not-saying-much-2019-05-25 | nan | nan | Over the next decade, there's a very good possibility that marijuana will be the fastest growing industry in North America. Depending on which Wall Street forecast you prefer, the legal cannabis industry could grow anywhere between 12% and 17% per year, through 2030.
But that's not the case in the early going. Although... | A mixed bag for Canada's biggest players As you might imagine, Canada's persistent supply problems have dealt quite a blow to the marijuana stocks that possess the largest premiums -- namely, Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB). Health Canada outlined a laundry list of labeling, warning, and safet... | A mixed bag for Canada's biggest players As you might imagine, Canada's persistent supply problems have dealt quite a blow to the marijuana stocks that possess the largest premiums -- namely, Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB). Here's a rundown of cannabis store sales since October, as reported i... | A mixed bag for Canada's biggest players As you might imagine, Canada's persistent supply problems have dealt quite a blow to the marijuana stocks that possess the largest premiums -- namely, Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB). Canadian pot sales hit a new high in March, but don't uncork the Cham... | A mixed bag for Canada's biggest players As you might imagine, Canada's persistent supply problems have dealt quite a blow to the marijuana stocks that possess the largest premiums -- namely, Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB). Second, this is a packaging problem. But the positive for Canopy Grow... |
38403.0 | 2019-05-24 00:00:00 UTC | Why Investors Shouldn’t Buy Tilray Stock Right Now | ACB | https://www.nasdaq.com/articles/why-investors-shouldnt-buy-tilray-stock-right-now-2019-05-24 | nan | nan | Tilray (NASDAQ:) stock has been one of the few popular cannabis stocks to struggle this year. Tilray stock was thrust into the spotlight when the shares went from $22.50 in August to a 52-week high of $300 in September. Yeah, that’ll get some attention!
But just because TLRY stock price once reached $300 does not mean ... | Over the last three months and the last six months, it’s the worst performer among a group of many marijuana stocks, including Tilray, Canopy Growth (NYSE:), Aurora Cannabis (NYSE:), New Age Beverages (NASDAQ:), Cronos Group (NASDAQ:) and even the Alternative Harvest ETF (NYSEARCA:). Many consider the most “blue chip” ... | Over the last three months and the last six months, it’s the worst performer among a group of many marijuana stocks, including Tilray, Canopy Growth (NYSE:), Aurora Cannabis (NYSE:), New Age Beverages (NASDAQ:), Cronos Group (NASDAQ:) and even the Alternative Harvest ETF (NYSEARCA:). Specifically, Tilray continues to m... | Tilray (NASDAQ:) stock has been one of the few popular cannabis stocks to struggle this year. But just because TLRY stock price once reached $300 does not mean that, at $44 now, TLRY stock is a six-bagger waiting to happen. Trading TLRY Stock When I look at the chart of TLRY stock, its massive downtrend isn’t hard to s... | Tilray stock was thrust into the spotlight when the shares went from $22.50 in August to a 52-week high of $300 in September. After all, many cannabis players are busy snapping up smaller companies right now. Trading TLRY Stock When I look at the chart of TLRY stock, its massive downtrend isn’t hard to spot. |
38404.0 | 2019-05-24 00:00:00 UTC | 6 Marijuana Stocks With Critical Levels to Watch | ACB | https://www.nasdaq.com/articles/6-marijuana-stocks-with-critical-levels-to-watch-2019-05-24 | nan | nan | In financial markets, there are certain price levels that are more significant than others with regard to the amount of supply and demand that exists at them. In addition, prices are always doing one of three things. They are either going up, going down or going nowhere. When understood and applied correctly, technical... | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) sells a lot of weed. ACB just reported its last quarter’s earnings and its gross margins came in at a hefty 55%. For example, suppose your broker or friend told you that ACB stock was worth $15 per share, suggesting you place your sell order at that level. | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) sells a lot of weed. ACB just reported its last quarter’s earnings and its gross margins came in at a hefty 55%. For example, suppose your broker or friend told you that ACB stock was worth $15 per share, suggesting you place your sell order at that level. | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) sells a lot of weed. ACB just reported its last quarter’s earnings and its gross margins came in at a hefty 55%. For example, suppose your broker or friend told you that ACB stock was worth $15 per share, suggesting you place your sell order at that level. | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) sells a lot of weed. ACB just reported its last quarter’s earnings and its gross margins came in at a hefty 55%. For example, suppose your broker or friend told you that ACB stock was worth $15 per share, suggesting you place your sell order at that level. |
38405.0 | 2019-05-24 00:00:00 UTC | Veggie Meat and Marijuana: The Hype (Cycle) Is Real | ACB | https://www.nasdaq.com/articles/veggie-meat-and-marijuana%3A-hype-cycle-real-2019-05-24 | nan | nan | On this episode of MarketFoolery, host Chris Hill chats with analyst Emily Flippen about three big stories on Wall Street. First, Alibaba's (NYSE: BABA) fantastic quarterly report prompted basically no reaction from the market. That probably has more to do with macro issues than anything Alibaba said or did...which mak... | Then, an update on the two best-known marijuana companies, Tilray (NASDAQ: TLRY) and Aurora Cannabis (NYSE: ACB). On this episode of MarketFoolery, host Chris Hill chats with analyst Emily Flippen about three big stories on Wall Street. That probably has more to do with macro issues than anything Alibaba said or did...... | Then, an update on the two best-known marijuana companies, Tilray (NASDAQ: TLRY) and Aurora Cannabis (NYSE: ACB). One, just that it happened; two, when Tim Hortons was looking for plant-based meat substitutes, they didn't go with Impossible Foods, which Burger King has been doing with the test of the Impossible Whopper... | Then, an update on the two best-known marijuana companies, Tilray (NASDAQ: TLRY) and Aurora Cannabis (NYSE: ACB). If you're interested in looking into the cannabis space, there's a lot of other companies, a lot of ancillary plays, that you can get into that have a lot less risk and a lot less exposure than companies li... | Then, an update on the two best-known marijuana companies, Tilray (NASDAQ: TLRY) and Aurora Cannabis (NYSE: ACB). But the fact that this is such a big company growing revenue at 51%, and they're seeing such an amazing growth through Alibaba Cloud, I mean, they really are doing everything. So if you're investing in comp... |
38406.0 | 2019-05-24 00:00:00 UTC | Canopy Growth Stock Could Regain Its 2019 Highs | ACB | https://www.nasdaq.com/articles/canopy-growth-stock-could-regain-its-2019-highs-2019-05-24 | nan | nan | Shares of Canopy Growth Corp (NYSE:) remain volatile, which comes as little surprise for investors. While CGC may be one of the more tame names among cannabis stocks, the industry is no stranger to volatility. Optimism towards CGC stock has grown over the past month, although CGC stock price has dropped recently.
Is th... | First, Bank of America’s analysts slapped a buy rating on Canopy Growth stock with a $52 price target. Later that day, reports began circulating that Canopy Growth may be working on a deal with Acreage Holdings (OTCMKTS:). Lee was previously with Constellation Brands, where he served as senior VP and CFO of the wine an... | Is the recent decline of CGC stock price a great buying opportunity or is the market sending a warning sign to the owners of Canopy Growth stock? As volatility has picked up in May, both market-wide and among cannabis stocks after Cronos Group (NASDAQ:), Aurora Cannabis (NYSE:) and other marijuana companies reported th... | Optimism towards CGC stock has grown over the past month, although CGC stock price has dropped recently. Is the recent decline of CGC stock price a great buying opportunity or is the market sending a warning sign to the owners of Canopy Growth stock? Trading CGC Stock Canopy Growth stock was trading in a long wedge for... | Is the recent decline of CGC stock price a great buying opportunity or is the market sending a warning sign to the owners of Canopy Growth stock? Recent Catalysts In mid-April, CGC stock price rallied on several positive notes. The stock is in a downward channel now, but it’s looking as if it’s starting to rise above i... |
38407.0 | 2019-05-24 00:00:00 UTC | How and Why Tilray Stock Is a Buy Here | ACB | https://www.nasdaq.com/articles/how-and-why-tilray-stock-buy-here-2019-05-24 | nan | nan | In the budding cannabis industry, there will be winners and losers. And for one-time heavyweight contender Tilray (NASDAQ:), a mixed earnings report has delivered another blow. But don’t think for a second Tilray stock is down for the count. Let me explain.
Source: Shutterstock
When a stock has lost 85% of its value in... | Tilray’s sales growth actually topped dearly held marijuana stock peers Cronos (NASDAQ:) and Aurora Cannabis’ (NYSE:) numbers over the same period. To be more fair, if marijuana stocks could be likened to a game of baseball, we’re barely done hearing the National Anthem for a market seemingly destined for secular growt... | And when that stock has only been a publicly traded company for 10 months, positioned within a secular growth market, it’s hard not to be alarmed. Tilray Stock’s Numbers The Canadian cannabis operator’s recent Q1 confessional offered Tilray investors some good news once they got beyond beyond its growing and wider-than... | Tilray Stock’s Numbers The Canadian cannabis operator’s recent Q1 confessional offered Tilray investors some good news once they got beyond beyond its growing and wider-than-expected loss. Tilray’s sales growth actually topped dearly held marijuana stock peers Cronos (NASDAQ:) and Aurora Cannabis’ (NYSE:) numbers over ... | Tilray Stock’s Numbers The Canadian cannabis operator’s recent Q1 confessional offered Tilray investors some good news once they got beyond beyond its growing and wider-than-expected loss. Tilray’s sales growth actually topped dearly held marijuana stock peers Cronos (NASDAQ:) and Aurora Cannabis’ (NYSE:) numbers over ... |
38408.0 | 2019-05-24 00:00:00 UTC | 11 Pot Stocks Now Listed on the NYSE or Nasdaq | ACB | https://www.nasdaq.com/articles/11-pot-stocks-now-listed-nyse-or-nasdaq-2019-05-24 | nan | nan | A decade ago, the idea of marijuana being a mainstream topic and burgeoning legal industry would probably have been laughable. At the time, there were still far more states that hadn't legalized medical pot than there were that had done so, and not a single country around the world allowed recreational cannabis sales.
... | Innovative Industrial Properties (NYSE: IIPR): December 2016, NYSE IPO Cronos Group: February 2018, Nasdaq uplisting Canopy Growth: May 2018, NYSE uplisting Tilray (NASDAQ: TLRY): July 2018, Nasdaq IPO Aurora Cannabis (NYSE: ACB): October 2018, NYSE uplisting Aphria: November 2018, NYSE uplisting HEXO: January 2019, NY... | Innovative Industrial Properties (NYSE: IIPR): December 2016, NYSE IPO Cronos Group: February 2018, Nasdaq uplisting Canopy Growth: May 2018, NYSE uplisting Tilray (NASDAQ: TLRY): July 2018, Nasdaq IPO Aurora Cannabis (NYSE: ACB): October 2018, NYSE uplisting Aphria: November 2018, NYSE uplisting HEXO: January 2019, NY... | Innovative Industrial Properties (NYSE: IIPR): December 2016, NYSE IPO Cronos Group: February 2018, Nasdaq uplisting Canopy Growth: May 2018, NYSE uplisting Tilray (NASDAQ: TLRY): July 2018, Nasdaq IPO Aurora Cannabis (NYSE: ACB): October 2018, NYSE uplisting Aphria: November 2018, NYSE uplisting HEXO: January 2019, NY... | Innovative Industrial Properties (NYSE: IIPR): December 2016, NYSE IPO Cronos Group: February 2018, Nasdaq uplisting Canopy Growth: May 2018, NYSE uplisting Tilray (NASDAQ: TLRY): July 2018, Nasdaq IPO Aurora Cannabis (NYSE: ACB): October 2018, NYSE uplisting Aphria: November 2018, NYSE uplisting HEXO: January 2019, NY... |
38409.0 | 2019-05-23 00:00:00 UTC | Aurora Cannabis Stock Continues to Gather Steam | ACB | https://www.nasdaq.com/articles/aurora-cannabis-stock-continues-gather-steam-2019-05-23 | nan | nan | Aurora Cannabis (NYSE:) reported its third-quarter results on May 15. They didn’t meet analysts’ consensus expectations. ACB stock temporarily lost some ground, only to regain those losses by the end of the day’s trading.
That’s a common occurrence when it comes to Aurora Cannabis stock and most other publicly traded p... | ACB stock temporarily lost some ground, only to regain those losses by the end of the day’s trading. In recent articles, I’ve changed my tune on ACB stock, as Aurora has demonstrated that it’s building a foundation that’s as wide as it is tall. Canada’s cannabis companies, including ACB, must be blamed for failing to d... | As a result, the faster Aurora gets to 25,000, 50,000, and 100,000 kilograms of cannabis produced in a quarter, the faster ACB stock will rise. ACB stock temporarily lost some ground, only to regain those losses by the end of the day’s trading. In recent articles, I’ve changed my tune on ACB stock, as Aurora has demons... | While there’s a risk that ACB will fall behind Canopy Growth (NYSE:) and Hexo (NYSEAmerican:HEXO) on the drinks front, potentially hurting ACB stock in the process, given ACB’s failure to make a partnership deal with a large beverage maker such as Constellation Brands (NYSE:) or Molson Coors (NYSE:TAP), it makes sense... | Canada’s cannabis companies, including ACB, must be blamed for failing to deliver enough supply for recreational pot smokers in the months following the legalization of recreational marijuana in October 2018. Strategy Is Positive for ACB Stock When I wrote my past articles, before I began to understand Aurora’s game pl... |
38410.0 | 2019-05-23 00:00:00 UTC | 1 Reason Aurora Cannabis Does, and Doesn't, Need a Brand-Name Partner | ACB | https://www.nasdaq.com/articles/1-reason-aurora-cannabis-does-and-doesnt-need-brand-name-partner-2019-05-23 | nan | nan | For better or worse, marijuana is the most popular investment opportunity right now, with the industry slated to see sales grow between fourfold and sixfold by 2030. Among the dozens upon dozens of pot stocks for investors to choose from, it's Aurora Cannabis (NYSE: ACB) that clocks in as the favorite.
According to Mar... | Among the dozens upon dozens of pot stocks for investors to choose from, it's Aurora Cannabis (NYSE: ACB) that clocks in as the favorite. With Robinhood being an app primarily favored by millennials, and the younger generation supporting the cannabis movement and legalization more so than seniors, it's pretty safe to c... | Among the dozens upon dozens of pot stocks for investors to choose from, it's Aurora Cannabis (NYSE: ACB) that clocks in as the favorite. Competition in the space is likely to be fierce, with Canopy Growth partnered with Constellation Brands, HEXO tied up with Molson Coors Brewing, Tilray in a joint venture with Anheus... | Among the dozens upon dozens of pot stocks for investors to choose from, it's Aurora Cannabis (NYSE: ACB) that clocks in as the favorite. Aurora's recently updated outlook for Aurora Sun, its largest organically constructed grow farm, now puts the company on track for an annual run rate of 625,000 kilos by mid-2020, wi... | Among the dozens upon dozens of pot stocks for investors to choose from, it's Aurora Cannabis (NYSE: ACB) that clocks in as the favorite. No beverage partner? No investment partner? |
38411.0 | 2019-05-23 00:00:00 UTC | 7 Marijuana Stocks to Play the CBD Trend | ACB | https://www.nasdaq.com/articles/7-marijuana-stocks-to-play-the-cbd-trend-2019-05-23 | nan | nan | [Editor’s note: This story was previously published in March 2019. It has since been updated and republished.]
Cannabidiol (CBD) is emerging as a red-hot category of the marijuana industry. CBD consists of compounds in the cannabis sativa plant that do not produce a high. In fact, over the years, CBDs have been shown t... | On its Q2 , Chief Corporate Officer Cam Battley said the company is poised “to launch a broad line of CBD based wellness product in the near future.” What’s more, ACB has been aggressive with its dealmaking. Cronos strong management team has built unique capabilities to compete globally across the medicinal, recreation... | Cronos strong management team has built unique capabilities to compete globally across the medicinal, recreational and nutraceutical categories.” Marijuana Stocks Poised to Benefit From CBD Legalization: Aurora Cannabis (ACB) Aurora Cannabis (NYSE:), a Canadian based cannabis producer, has been building up its CBD busi... | Cronos strong management team has built unique capabilities to compete globally across the medicinal, recreational and nutraceutical categories.” Marijuana Stocks Poised to Benefit From CBD Legalization: Aurora Cannabis (ACB) Aurora Cannabis (NYSE:), a Canadian based cannabis producer, has been building up its CBD busi... | Cronos strong management team has built unique capabilities to compete globally across the medicinal, recreational and nutraceutical categories.” Marijuana Stocks Poised to Benefit From CBD Legalization: Aurora Cannabis (ACB) Aurora Cannabis (NYSE:), a Canadian based cannabis producer, has been building up its CBD busi... |
38412.0 | 2019-05-22 00:00:00 UTC | A Detailed Look at How Aurora Cannabis Generated Revenue in the Third Quarter | ACB | https://www.nasdaq.com/articles/detailed-look-how-aurora-cannabis-generated-revenue-third-quarter-2019-05-22 | nan | nan | There might be no industry more popular among investors right now than marijuana; and there's good reason for that. The cannabis industry is expected to grow by as much as 19% a year on a compound annual basis between 2015 and 2030 -- that's if projections of $75 billion in annual worldwide sales by 2030 from Cowen Gro... | Although there are dozens upon dozens of marijuana stocks for investors to choose from, none has been more polarizing than Aurora Cannabis (NYSE: ACB). Last week, Aurora Cannabis lifted the hood on its fiscal third quarter (Jan. 1, 2019 – March 31, 2019) and gave investors a view of what's been going on with its busine... | Although there are dozens upon dozens of marijuana stocks for investors to choose from, none has been more polarizing than Aurora Cannabis (NYSE: ACB). How cannabis brings in the green for Aurora Of Aurora's CA$65.15 million in Q3 2019 net sales, CA$58.65 million (90% of sales) was derived from selling cannabis and der... | Although there are dozens upon dozens of marijuana stocks for investors to choose from, none has been more polarizing than Aurora Cannabis (NYSE: ACB). With regard to the medical cannabis sales, CA$16.58 million was related to dried flower, CA$8.5 million was from extracts (e.g., oils), and CA$4 million was brought in ... | Although there are dozens upon dozens of marijuana stocks for investors to choose from, none has been more polarizing than Aurora Cannabis (NYSE: ACB). Wrapping things up with Aurora's ancillary operations Aurora's ancillary sources of revenue accounted for CA$6.49 million in sales in the third quarter, up from CA$5.29... |
38413.0 | 2019-05-22 00:00:00 UTC | Aurora Cannabis Stock Is Attractively Valued After A Huge Q3 | ACB | https://www.nasdaq.com/articles/aurora-cannabis-stock-attractively-valued-after-huge-q3-2019-05-22 | nan | nan | Aurora Cannabis Inc. (NYSE:) had an extremely productive fiscal third quarter. Metrics looked very positive across the board: solid revenue growth; active registered patients up; cash cost to produce per gram down; production volume increased materially.
Source: Shutterstock
Everything is heading in the right direction... | Using the market cap per kilograms sold as a valuation metric, ACB stock also looks much cheaper than other cannabis companies. ACB has even announced that famed activist investor, Nelson Peltz, joined the company as a strategic adviser. This is a big win for ACB stock as Peltz’s network and business perspective will p... | What’s Ahead for ACB Stock In addition to being on track to deliver positive EBITDA in Q4, Aurora is also on track to increase sales meaningfully with production facilities targeting over 25,000 kg of cannabis available for sale. ACB has even announced that famed activist investor, Nelson Peltz, joined the company as a... | What This Means for ACB Stock What this all means is that ACB stock is on track to delivery positive EBITDA in Q4 2019. What’s Ahead for ACB Stock In addition to being on track to deliver positive EBITDA in Q4, Aurora is also on track to increase sales meaningfully with production facilities targeting over 25,000 kg of... | Using the market cap per kilograms sold as a valuation metric, ACB stock also looks much cheaper than other cannabis companies. ACB has even announced that famed activist investor, Nelson Peltz, joined the company as a strategic adviser. This is a big win for ACB stock as Peltz’s network and business perspective will p... |
38414.0 | 2019-05-22 00:00:00 UTC | It’s Time to Load Up on CGC Stock Again | ACB | https://www.nasdaq.com/articles/its-time-load-cgc-stock-again-2019-05-22 | nan | nan | In early April I wrote about going long Canopy Growth (NYSE:) stock. That trade paid off quickly but after peaking at $52.50 per share CGC stock gave it back and has reverted to support. While this sounds disappointing it is where the opportunity lies today.
Source: Shutterstock
It is time to reload almost exactly the ... | So far, CGC and ACB are up more than 65% year to date — four times the performance of the S&P 500. That trade paid off quickly but after peaking at $52.50 per share CGC stock gave it back and has reverted to support. As more states follow the early movers, the North America consumption markets will grow exponentially. | So far, CGC and ACB are up more than 65% year to date — four times the performance of the S&P 500. In early April I wrote about going long Canopy Growth (NYSE:) stock. But First, Canopy Growth Fundamentals The whole cannabis stock sector is speculative at best. | So far, CGC and ACB are up more than 65% year to date — four times the performance of the S&P 500. That trade paid off quickly but after peaking at $52.50 per share CGC stock gave it back and has reverted to support. But First, Canopy Growth Fundamentals The whole cannabis stock sector is speculative at best. | So far, CGC and ACB are up more than 65% year to date — four times the performance of the S&P 500. Companies like Canopy Growth are trying to establish a legitimate business on Wall Street for the first time ever. Canopy Growth fundamentals from the traditional point of view are scary. |
38415.0 | 2019-05-22 00:00:00 UTC | Aurora Cannabis: Here’s How to Buy ACB Stock | ACB | https://www.nasdaq.com/articles/aurora-cannabis%3A-heres-how-buy-acb-stock-2019-05-22 | nan | nan | A slight earnings whiff is no match for budding trends off and on the price chart in Aurora Cannabis (NYSE:ACB). But bullish investors should wait for a bit more green to appear on the weekly view of ACB stock before buying. Let me explain.
Source: Shutterstock
It’s not difficult to grow uneasy when one of the marijuan... | For one, ACB’s stronger-than-expected third-quarter sales growth during a rather weak operating environment for Canadian cannabis outfits was nothing short of a solid win. As InvestorPlace’s Luke Lango also notes, ACB stock’s in valuation make Aurora ripe for investment similar to Canopy Growth (NYSE:CGC) or Cronos (NA... | A slight earnings whiff is no match for budding trends off and on the price chart in Aurora Cannabis (NYSE:ACB). But bullish investors should wait for a bit more green to appear on the weekly view of ACB stock before buying. ACB Stock Weekly Chart After moving more or less in lockstep with the broader market from last ... | But bullish investors should wait for a bit more green to appear on the weekly view of ACB stock before buying. As InvestorPlace’s Luke Lango also notes, ACB stock’s in valuation make Aurora ripe for investment similar to Canopy Growth (NYSE:CGC) or Cronos (NASDAQ:CRON) and bodes well for higher prices. ACB Stock Weekl... | But bullish investors should wait for a bit more green to appear on the weekly view of ACB stock before buying. A slight earnings whiff is no match for budding trends off and on the price chart in Aurora Cannabis (NYSE:ACB). But in the case of ACB stock, it also fails to appreciate the big picture — one which looks ver... |
38416.0 | 2019-05-21 00:00:00 UTC | 3 Pot Stocks Wall Street Bought in the First Quarter | ACB | https://www.nasdaq.com/articles/3-pot-stocks-wall-street-bought-first-quarter-2019-05-21 | nan | nan | Whether you realize it or not, mid-May a special time of the year for investors -- and I'm not talking about the barrage of earnings reports that have hit the newswires over the past couple of weeks. No, I'm talking about May 15 being the deadline for primetime money managers and Wall Street institutions to file Form 1... | Aurora Cannabis The first pot stock that saw modest buying in the first quarter from institutional investors was Aurora Cannabis (NYSE: ACB). With tobacco cigarette shipments falling in the U.S., and the adult smoking rate hitting at least a 50-year low, Altria needs new channels of revenue, and partnering on vape prod... | Aurora Cannabis The first pot stock that saw modest buying in the first quarter from institutional investors was Aurora Cannabis (NYSE: ACB). Previously expected to span 1.2 million square feet and yield more than 150,000 kilos a year, Aurora Cannabis announced that it would be boosting capacity to 1.62 million square ... | Aurora Cannabis The first pot stock that saw modest buying in the first quarter from institutional investors was Aurora Cannabis (NYSE: ACB). While most of Wall Street has been focused on what these investment funds did with regard to FAANG stocks in the first quarter -- Facebook, Amazon, Apple, Netflix, and Alphabet, ... | Aurora Cannabis The first pot stock that saw modest buying in the first quarter from institutional investors was Aurora Cannabis (NYSE: ACB). Put simply, Form 13F is a required disclosure of investment holdings for investment funds and hedge funds with more than $100 million in assets under management. 10 stocks we lik... |
38417.0 | 2019-05-21 00:00:00 UTC | 3 Reasons the Illicit Marijuana Market Won't Be Marginalized | ACB | https://www.nasdaq.com/articles/3-reasons-illicit-marijuana-market-wont-be-marginalized-2019-05-21 | nan | nan | Investors long cannabis stocks have been making some dangerous connections between the marijuana industry and the market for alcoholic beverages following prohibition. You're about to see that they're hardly even related.
In case you haven't been paying attention, sales of government-sanctioned cannabis throughout Cana... | In case you haven't been paying attention, sales of government-sanctioned cannabis throughout Canada have been stagnating at a level too low for big producers like Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) to scratch out a profit. Investors long cannabis stocks have been making some dangerous connection... | In case you haven't been paying attention, sales of government-sanctioned cannabis throughout Canada have been stagnating at a level too low for big producers like Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) to scratch out a profit. In theory, all cannabis products must originate from a state-licensed pro... | In case you haven't been paying attention, sales of government-sanctioned cannabis throughout Canada have been stagnating at a level too low for big producers like Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) to scratch out a profit. Investors long cannabis stocks have been making some dangerous connection... | In case you haven't been paying attention, sales of government-sanctioned cannabis throughout Canada have been stagnating at a level too low for big producers like Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) to scratch out a profit. Across the EU, and just about anywhere marijuana has been decriminalized ... |
38418.0 | 2019-05-21 00:00:00 UTC | Aurora Cannabis, Cronos Group, and Tilray Earnings Results Are In: Here's What They Could Mean for Canopy Growth | ACB | https://www.nasdaq.com/articles/aurora-cannabis-cronos-group-and-tilray-earnings-results-are-%3A-heres-what-they-could-mean | nan | nan | If you've been keeping score, three of the top four biggest Canadian marijuana producers by market cap have reported their latest earnings results. Cronos Group (NASDAQ: CRON) kicked things off on May 9, with Tilray (NASDAQ: TLRY) and Aurora Cannabis (NYSE: ACB) following with their quarterly updates last week.
But the... | Cronos Group (NASDAQ: CRON) kicked things off on May 9, with Tilray (NASDAQ: TLRY) and Aurora Cannabis (NYSE: ACB) following with their quarterly updates last week. While investors wait for the big company to report its results, there are a few things from the updates provided by Aurora, Cronos, and Tilray that could g... | Cronos Group (NASDAQ: CRON) kicked things off on May 9, with Tilray (NASDAQ: TLRY) and Aurora Cannabis (NYSE: ACB) following with their quarterly updates last week. If you've been keeping score, three of the top four biggest Canadian marijuana producers by market cap have reported their latest earnings results. With Ge... | Cronos Group (NASDAQ: CRON) kicked things off on May 9, with Tilray (NASDAQ: TLRY) and Aurora Cannabis (NYSE: ACB) following with their quarterly updates last week. While investors wait for the big company to report its results, there are a few things from the updates provided by Aurora, Cronos, and Tilray that could g... | Cronos Group (NASDAQ: CRON) kicked things off on May 9, with Tilray (NASDAQ: TLRY) and Aurora Cannabis (NYSE: ACB) following with their quarterly updates last week. Cronos announced revenue that was up 15% over the previous quarter. Again, Aurora is the best company to look at to get a feel for how Canopy Growth's inte... |
38419.0 | 2019-05-20 00:00:00 UTC | Why Strong Q3 Numbers Make Aurora Stock Worth Buying | ACB | https://www.nasdaq.com/articles/why-strong-q3-numbers-make-aurora-stock-worth-buying-2019-05-20 | nan | nan | Aurora Canncbabis (NYSE:) stock traded higher in mid-May after the Canadian cannabis giant reported third-quarter numbers that, while short of expectations, broadly confirmed that ACB is benefiting from favorable underlying trends. Investors cheered the favorable results, and ACB stock traded slightly higher in respon... | Aurora Canncbabis (NYSE:) stock traded higher in mid-May after the Canadian cannabis giant reported third-quarter numbers that, while short of expectations, broadly confirmed that ACB is benefiting from favorable underlying trends. Aurora didn’t receive a large investment like Canopy or Cronos, yet But, considering th... | As a result, now seems like a good time to get bullish on ACB stock, since the relative valuation discount of Aurora Cannabis stock won’t last forever. Aurora Canncbabis (NYSE:) stock traded higher in mid-May after the Canadian cannabis giant reported third-quarter numbers that, while short of expectations, broadly con... | Aurora Canncbabis (NYSE:) stock traded higher in mid-May after the Canadian cannabis giant reported third-quarter numbers that, while short of expectations, broadly confirmed that ACB is benefiting from favorable underlying trends. The Bottom Line on ACB Stock Aurora’s third-quarter numbers were actually much better t... | The Bottom Line on ACB Stock Aurora’s third-quarter numbers were actually much better than most expected, and imply that Aurora is extending its leadership position in the Canadian cannabis market. Aurora Canncbabis (NYSE:) stock traded higher in mid-May after the Canadian cannabis giant reported third-quarter numbers ... |
38420.0 | 2019-05-20 00:00:00 UTC | These Billionaire Money Managers Bought Aurora Cannabis Stock in the First Quarter | ACB | https://www.nasdaq.com/articles/these-billionaire-money-managers-bought-aurora-cannabis-stock-first-quarter-2019-05-20 | nan | nan | It's that time again, folks -- and, no, I'm not talking about air-conditioner weather.
Last week (on May 15), the deadline was hit for money managers with more than $100 million in asset under management to file Form 13F with the Securities and Exchange Commission. Form 13F lists all the holdings of prominent investmen... | Namely, that the most popular marijuana stock among investors, Aurora Cannabis (NYSE: ACB), found its way onto Wall Street's buy list. These external sales channels will prove especially important if and when Canadian dried cannabis flower becomes oversupplied and commoditized, as we've seen happen in select U.S. state... | Namely, that the most popular marijuana stock among investors, Aurora Cannabis (NYSE: ACB), found its way onto Wall Street's buy list. Simons' fund, which had $110 billion in assets under management at the end of the first quarter, opened a position in Aurora by purchasing 788,595 shares, worth $7.1 million. See the 10... | Namely, that the most popular marijuana stock among investors, Aurora Cannabis (NYSE: ACB), found its way onto Wall Street's buy list. Billionaires are buying Aurora Cannabis Although much of the focus following the release of 13Fs was on big-name money managers buying into the FAANG stocks -- Facebook, Amazon, Apple, ... | Namely, that the most popular marijuana stock among investors, Aurora Cannabis (NYSE: ACB), found its way onto Wall Street's buy list. As a result, the company's outstanding share count has risen by about 1 billion shares in less than five years. 10 stocks we like better than Aurora Cannabis Inc. |
38421.0 | 2019-05-19 00:00:00 UTC | Aurora Cannabis Had a Great Quarter -- but Here's What We Still Don't Know | ACB | https://www.nasdaq.com/articles/aurora-cannabis-had-great-quarter-heres-what-we-still-dont-know-2019-05-19 | nan | nan | You really can't find too much to complain about with Aurora Cannabis' (NYSE: ACB) fiscal 2019 third-quarter results. The Canadian marijuana producer delivered strong sales growth that was better than many expected. Even though Aurora posted a big net loss, most of it stemmed from a noncash fair value loss in the compa... | You really can't find too much to complain about with Aurora Cannabis' (NYSE: ACB) fiscal 2019 third-quarter results. Some might have even gotten the impression that Chief Corporate Officer Cam Battley was downplaying the search for a partner somewhat, with his statement that Aurora is working with Peltz "on multiple i... | You really can't find too much to complain about with Aurora Cannabis' (NYSE: ACB) fiscal 2019 third-quarter results. Tilray CEO Brendan Kennedy stated in his company's quarterly conference call that Tilray "has been inundated with contacts from Fortune 500 companies who are interested in exploring partnerships" with t... | You really can't find too much to complain about with Aurora Cannabis' (NYSE: ACB) fiscal 2019 third-quarter results. He noted that Aurora's spin-off company Australis Capital is doing deals in the U.S. and that Aurora has rights to buy a significant stake in the company in the future. Booth said he still loses sleep o... | You really can't find too much to complain about with Aurora Cannabis' (NYSE: ACB) fiscal 2019 third-quarter results. However, we still don't know what Aurora's plans for entering the U.S. are. He noted that Aurora's spin-off company Australis Capital is doing deals in the U.S. and that Aurora has rights to buy a signi... |
38422.0 | 2019-05-19 00:00:00 UTC | How Did Tilray Stack Up to the Competition? | ACB | https://www.nasdaq.com/articles/how-did-tilray-stack-competition-2019-05-19 | nan | nan | In the market for licensed Cannabis, Tilray (NASDAQ: TLRY) only has three larger competitors. Aurora Cannabis (NYSE: ACB), is much larger than Tilray, and Cronos Group (NASDAQ: CRON) is nearly the same size. Canopy Growth's $15.4 billion market cap is more than three times Tilray's size, and since Canopy hasn't reporte... | Aurora Cannabis (NYSE: ACB), is much larger than Tilray, and Cronos Group (NASDAQ: CRON) is nearly the same size. Cronos Group couldn't outperform its larger competitor, but a 54% gross margin in the first quarter still beats Tilray's performance by a mile. In February, Tilray acquired Natura Holdings, a large licensed... | Aurora Cannabis (NYSE: ACB), is much larger than Tilray, and Cronos Group (NASDAQ: CRON) is nearly the same size. Over the same time frame, top-line revenue at Aurora Cannabis grew 20% to CA$65.1 million, and Cronos Group came in last, with revenue that rose just 16% to a meager CA$6.5 million. During the same time fra... | Aurora Cannabis (NYSE: ACB), is much larger than Tilray, and Cronos Group (NASDAQ: CRON) is nearly the same size. During the first quarter, Tilray's cost of goods sold was so high that the company produced a gross profit of just CA$7.2 million, or around 23% of revenue. In the first quarter, Tilray reported sales, gene... | Aurora Cannabis (NYSE: ACB), is much larger than Tilray, and Cronos Group (NASDAQ: CRON) is nearly the same size. During the first quarter, Tilray's cost of goods sold was so high that the company produced a gross profit of just CA$7.2 million, or around 23% of revenue. Aurora was far more efficient than Tilray in the ... |
38423.0 | 2019-05-18 00:00:00 UTC | 3 Brand-Name Food and Beverage Companies That Want In on the Marijuana Craze | ACB | https://www.nasdaq.com/articles/3-brand-name-food-and-beverage-companies-want-marijuana-craze-2019-05-18 | nan | nan | Legal marijuana is one of the fastest growing industries in North America right now, and there's a very good chance it'll stay this way for at least a few more years. Having generated $12.2 billion in global sales last year, per Arcview Market Research and BDS Analytics, legal pot sales are expected to surge to more th... | As a reminder, Coca-Cola was in talks with both Aphria (NYSE: APHA) and Aurora Cannabis (NYSE: ACB) last year about a possible equity stake and/or partnership, but nothing wound up materializing from these discussions. In early August, the market was surprised when Molson Coors Brewing announced that it would be formin... | As a reminder, Coca-Cola was in talks with both Aphria (NYSE: APHA) and Aurora Cannabis (NYSE: ACB) last year about a possible equity stake and/or partnership, but nothing wound up materializing from these discussions. Brand-name partnership opportunity pick up for pot stocks The potential of partnering a brand-name co... | As a reminder, Coca-Cola was in talks with both Aphria (NYSE: APHA) and Aurora Cannabis (NYSE: ACB) last year about a possible equity stake and/or partnership, but nothing wound up materializing from these discussions. Brand-name partnership opportunity pick up for pot stocks The potential of partnering a brand-name co... | As a reminder, Coca-Cola was in talks with both Aphria (NYSE: APHA) and Aurora Cannabis (NYSE: ACB) last year about a possible equity stake and/or partnership, but nothing wound up materializing from these discussions. Brand-name partnership opportunity pick up for pot stocks The potential of partnering a brand-name co... |
38424.0 | 2019-05-18 00:00:00 UTC | Better Buy: Aphria vs. Aurora Cannabis | ACB | https://www.nasdaq.com/articles/better-buy%3A-aphria-vs.-aurora-cannabis-2019-05-18 | nan | nan | You might think that the choice between Aphria (NYSE: APHA) and Aurora Cannabis (NYSE: ACB) is an easy one. Aphria underperformed Aurora last year and has done the same in 2019 so far -- and by a wide margin.
But there's a lot more to consider than just past stock performance in choosing between Aphria and Aurora. Whic... | You might think that the choice between Aphria (NYSE: APHA) and Aurora Cannabis (NYSE: ACB) is an easy one. The company was hit by short-seller allegations in late 2018 that it drastically overpaid for LATAM Holdings in a transaction that benefited key Aphria insiders. The company teamed up with Southern Glazer's, the ... | You might think that the choice between Aphria (NYSE: APHA) and Aurora Cannabis (NYSE: ACB) is an easy one. With its Aphria One facility now licensed, the company claims an annualized production run rate of 115,000 kilograms. The most important of these is Germany, where the company was one of three to be awarded a lic... | You might think that the choice between Aphria (NYSE: APHA) and Aurora Cannabis (NYSE: ACB) is an easy one. The case for Aurora Cannabis Pretty much everything seems to be going right for Aurora Cannabis these days. But Aurora's market cap is more than five times the size of Aphria's market cap. | You might think that the choice between Aphria (NYSE: APHA) and Aurora Cannabis (NYSE: ACB) is an easy one. Aphria has operations in 10 countries outside of Canada with medical cannabis markets. Aurora doesn't have a partner from outside the cannabis industry like some of its peers do. |
38425.0 | 2019-05-18 00:00:00 UTC | You'll Never Guess Who's Betting Against Canadian Cannabis Stocks | ACB | https://www.nasdaq.com/articles/youll-never-guess-whos-betting-against-canadian-cannabis-stocks-2019-05-18 | nan | nan | Curaleaf Holdings (NASDAQOTH: CURLF) is the largest multistate operator focused on tightly regulated marijuana markets along the East Coast. Curaleaf's executive chairman, Boris Jordan, also runs Measure 8, a venture fund that recently stirred up some controversy with a questionable acquisition.
In the near future, Mea... | If this figure doesn't start rising again, Aurora Cannabis (NYSE: ACB) will soon be able to supply the entire Canadian market for licensed marijuana while running at half capacity. Canopy Growth, Aurora Cannabis, and many of their giant Canadian peers will never run all of their greenhouses at full capacity, but market... | If this figure doesn't start rising again, Aurora Cannabis (NYSE: ACB) will soon be able to supply the entire Canadian market for licensed marijuana while running at half capacity. Why buying U.S. cannabis businesses makes sense In the U.S., annual legal marijuana sales climbed to $10.4 billion in 2018, and there's sti... | If this figure doesn't start rising again, Aurora Cannabis (NYSE: ACB) will soon be able to supply the entire Canadian market for licensed marijuana while running at half capacity. In the near future, Measure 8 wants to launch a hedge fund that will bet on U.S. marijuana stocks and against Canadian cannabis producers a... | If this figure doesn't start rising again, Aurora Cannabis (NYSE: ACB) will soon be able to supply the entire Canadian market for licensed marijuana while running at half capacity. In the near future, Measure 8 wants to launch a hedge fund that will bet on U.S. marijuana stocks and against Canadian cannabis producers a... |
38426.0 | 2019-05-17 00:00:00 UTC | How Trade War 2.0 Benefits Struggling Cronos Stock | ACB | https://www.nasdaq.com/articles/how-trade-war-2.0-benefits-struggling-cronos-stock-2019-05-17 | nan | nan | As things stand now, cannabis firm Cronos Group (NASDAQ:) is a two-faced investment. CRON stock recovered well from late last year’s volatility, as CRON stock is up nearly 49% since the beginning of January. But Cronos stock shed 30% since March 1, putting a sour taste in recent buyers’ mouths.
Source: Shutterstock
Fun... | CRON Stock Has Received a Massive Tailwind One of the more surprising developments in geopolitics recently is that the trade war is back on. Since much of this country’s agricultural base is located in conservative regions, Trump can’t play hardball with the Chinese without incurring political penalties. If Kilhefner h... | As things stand now, cannabis firm Cronos Group (NASDAQ:) is a two-faced investment. For weeks, it appeared that the Trump administration and its Chinese counterpart were ready to make a deal. If Kilhefner hasn’t dumped his shares of Cronos Group stock, I’d recommend he bite the bullet and wait. | CRON stock recovered well from late last year’s volatility, as CRON stock is up nearly 49% since the beginning of January. For weeks, it appeared that the Trump administration and its Chinese counterpart were ready to make a deal. If Kilhefner hasn’t dumped his shares of Cronos Group stock, I’d recommend he bite the bu... | However, Kilhefner now buying Cronos stock. For weeks, it appeared that the Trump administration and its Chinese counterpart were ready to make a deal. Trump will either have to give in to the Chinese or make concessions on the cannabis legalization front. |
38427.0 | 2019-05-17 00:00:00 UTC | The Bullish Thesis for Tilray Stock Is Still Alive and Well | ACB | https://www.nasdaq.com/articles/bullish-thesis-tilray-stock-still-alive-and-well-2019-05-17 | nan | nan | Every so often, Wall Street experiences a craze that is fascinating like Bitcoin in 2017. But now it’s the cannabis stocks and Tilray (NASDAQ:) has been a wild one to watch. It went public last year and within two months it had rallied 1,000%. 2019 has not been kind to TLRY stock as it’s down 32% year-to-date, yet it i... | Source: Shutterstock Today’s write up is to encourage those who like the stock to hold it and to also discourage those who want to short it. Maybe, but unlike bitcoin where the concept escapes 99% of all people, everyone knows what cannabis is and is immediately interested in learning more about it. So the bottom line ... | Before you send me hate mail on this, I am not calling TLRY stock dead. To that, management reported a big top line beat and 195% growth year over year. Bottom Line on TLRY Stock The hoopla around cannabis stocks like Tilray is that they will disrupt so many huge markets that their upside potential should also be massi... | The stock spiked 6% on the headline and it is holding the zone decently given the overall stock market jitters. Bottom Line on TLRY Stock The hoopla around cannabis stocks like Tilray is that they will disrupt so many huge markets that their upside potential should also be massive. Netflix still gets a pass on profitab... | So what’s a fair value for TLRY stock? The U.S. market is an important one and many states will soon follow the ones that have already legalized it. Bottom Line on TLRY Stock The hoopla around cannabis stocks like Tilray is that they will disrupt so many huge markets that their upside potential should also be massive. |
38428.0 | 2019-05-17 00:00:00 UTC | 1 Common, but Sad, Fact About the Biggest Marijuana ETFs | ACB | https://www.nasdaq.com/articles/1-common-sad-fact-about-biggest-marijuana-etfs-2019-05-17 | nan | nan | There's a very real possibility that the legal marijuana industry will be the greatest growth story of our generation. According to ArcView Market Research and BDS Analytics, the green rush produced $5.4 billion in worldwide legal sales in 2015. But based on estimates from Wall Street investment bank Cowen Group, sales... | Its top holdings are Canopy Growth (NYSE: CGC) with a 12.83% share and Aurora Cannabis (NYSE: ACB) at 10.84%. For example, despite becoming the first industrialized country to give recreational marijuana the green light in October, Canada has been contending with a persistent shortage of dried flower since dispensary d... | Its top holdings are Canopy Growth (NYSE: CGC) with a 12.83% share and Aurora Cannabis (NYSE: ACB) at 10.84%. Today, the Horizons Marijuana Life Sciences ETF holds nearly five dozen pot stocks with various weightings, and it has about 934 million Canadian dollars in net assets. However, there's a pretty sad, but true, ... | Its top holdings are Canopy Growth (NYSE: CGC) with a 12.83% share and Aurora Cannabis (NYSE: ACB) at 10.84%. Today, the Horizons Marijuana Life Sciences ETF holds nearly five dozen pot stocks with various weightings, and it has about 934 million Canadian dollars in net assets. Though the Horizons Marijuana Life Scienc... | Its top holdings are Canopy Growth (NYSE: CGC) with a 12.83% share and Aurora Cannabis (NYSE: ACB) at 10.84%. Even the green rush has risks Unfortunately, even the greatest growth stories come with some pretty serious risks and volatility. The Horizons Marijuana Life Sciences ETF might appear well diversified with 58 d... |
38429.0 | 2019-05-16 00:00:00 UTC | Thursday’s Vital Data: Walmart, Beyond Meat and Aurora Cannabis | ACB | https://www.nasdaq.com/articles/thursdays-vital-data%3A-walmart-beyond-meat-and-aurora-cannabis-2019-05-16 | nan | nan | U.S. stock futures are trading slightly higher this morning in an attempt to rally for the third day in a row. The calm open comes as a refreshing break from the recent streak of large overnight down gaps.
Heading into the open, futures on the Dow Jones Industrial Average are up 0.32%, and S&P 500 futures are higher by... | Aurora Cannabis (ACB) Aurora Cannabis gave investors a peek behind the curtain this week, revealing their earnings and sales data for the quarter. ACB lost 16 cents per share far outpacing calls for a 5 cent loss. ACB stock remains stuck in a range and is below its 20-day and 50-day moving average. | Aurora Cannabis (ACB) Aurora Cannabis gave investors a peek behind the curtain this week, revealing their earnings and sales data for the quarter. ACB lost 16 cents per share far outpacing calls for a 5 cent loss. ACB stock remains stuck in a range and is below its 20-day and 50-day moving average. | Aurora Cannabis (ACB) Aurora Cannabis gave investors a peek behind the curtain this week, revealing their earnings and sales data for the quarter. ACB lost 16 cents per share far outpacing calls for a 5 cent loss. ACB stock remains stuck in a range and is below its 20-day and 50-day moving average. | Aurora Cannabis (ACB) Aurora Cannabis gave investors a peek behind the curtain this week, revealing their earnings and sales data for the quarter. ACB lost 16 cents per share far outpacing calls for a 5 cent loss. ACB stock remains stuck in a range and is below its 20-day and 50-day moving average. |
38430.0 | 2019-05-16 00:00:00 UTC | Should You Buy Canopy Growth Stock? 3 Pros, 3 Cons | ACB | https://www.nasdaq.com/articles/should-you-buy-canopy-growth-stock-3-pros-3-cons-2019-05-16 | nan | nan | Canopy Growth (NYSE:) just isn’t getting as high as it used to. But CGC stock isn’t alone. The marijuana stocks have lost a lot of their buzz lately. The sector fund, the Alternative Harvest ETF (NYSEARCA:) has dropped roughly 15% from its recent highs in March. On top of that, its current $33 share price is well off t... | On top of that, its current $33 share price is well off the $45 level where marijuana stocks peaked just before Canada’s legalization went into effect last fall. Valuation Is Still Strained: Canopy Growth — and most of its publicly traded rivals that focus on recreational marijuana — have yet to deliver compelling earn... | With the company making major acquisitions ahead of earnings and short sellers betting the farm against the stock, expect CGC stock to make big moves in coming weeks. CGC Stock Cons Acreage Deal Isn’t A Standard Acquisition: Canopy Growth recently announced a deal to purchase Acreage Holdings (OTCMKTS:). Not only are t... | CGC Stock Cons Acreage Deal Isn’t A Standard Acquisition: Canopy Growth recently announced a deal to purchase Acreage Holdings (OTCMKTS:). CGC Stock Hitting Major Resistance: From a technical analysis standpoint, Canopy Growth stock is starting to get itself into trouble. CGC Stock Holding Up Better: Canopy Growth stoc... | That is because it is paying a not insubstantial $300 million upfront for the deal, along with far more than that in CGC stock once the deal closes. But at least it is still somewhere near its recent trading highs. That said, if you are already considering taking a long position, high short interest could be the thing ... |
38431.0 | 2019-05-16 00:00:00 UTC | Aurora Cannabis: 8 Facts About Its Latest Quarter | ACB | https://www.nasdaq.com/articles/aurora-cannabis%3A-8-facts-about-its-latest-quarter-2019-05-16 | nan | nan | Canada's recreational marijuana market is valued at over $5 billion Canadian ($3.71 billion) per year, and that means that leading marijuana stocks are poised to see sales skyrocket following legalization last October.
To make sure it gets its fair share of this opportunity, Aurora Cannabis (NYSE: ACB) has been pouring... | To make sure it gets its fair share of this opportunity, Aurora Cannabis (NYSE: ACB) has been pouring money into acquisitions and greenhouse expansion. Earlier this week, management reported quarterly financial results showing its strategy is paying off with rapid revenue growth. It began exporting full-spectrum cannab... | To make sure it gets its fair share of this opportunity, Aurora Cannabis (NYSE: ACB) has been pouring money into acquisitions and greenhouse expansion. 1: Rapidly rising revenue The company's net marijuana revenue increased 305% year over year to CA$65.1 million in the quarter, up from CA$54.2 million in its previous q... | To make sure it gets its fair share of this opportunity, Aurora Cannabis (NYSE: ACB) has been pouring money into acquisitions and greenhouse expansion. 1: Rapidly rising revenue The company's net marijuana revenue increased 305% year over year to CA$65.1 million in the quarter, up from CA$54.2 million in its previous q... | To make sure it gets its fair share of this opportunity, Aurora Cannabis (NYSE: ACB) has been pouring money into acquisitions and greenhouse expansion. Medical marijuana sales improved 12% sequentially to CA$29.1 million, making this the first quarter in which recreational sales accounted for more sales than medical ma... |
38432.0 | 2019-05-16 00:00:00 UTC | The 3 Best Marijuana Stocks to Buy Right Now | ACB | https://www.nasdaq.com/articles/the-3-best-marijuana-stocks-to-buy-right-now-2019-05-16 | nan | nan | Since their inception, marijuana stocks attracted significant attention. Due to both investment sentiment – and let’s face it, raw emotions – the cannabis sector absolutely skyrocketed. But now, the segment is attracting attention for failing to live up to analysts’ expectations. Is the honeymoon phase over for weed?
H... | Here are the best three marijuana stocks to buy right now: Aurora Cannabis (ACB) Source: Shutterstock Aurora Cannabis (NYSE:) recently issued its earnings results for the first quarter of 2019. Let’s just say the print wasn’t exactly great for ACB stock. With such a wide gap, conventional wisdom dictates that you shoul... | Here are the best three marijuana stocks to buy right now: Aurora Cannabis (ACB) Source: Shutterstock Aurora Cannabis (NYSE:) recently issued its earnings results for the first quarter of 2019. Let’s just say the print wasn’t exactly great for ACB stock. With such a wide gap, conventional wisdom dictates that you shoul... | Here are the best three marijuana stocks to buy right now: Aurora Cannabis (ACB) Source: Shutterstock Aurora Cannabis (NYSE:) recently issued its earnings results for the first quarter of 2019. Let’s just say the print wasn’t exactly great for ACB stock. With such a wide gap, conventional wisdom dictates that you shoul... | Here are the best three marijuana stocks to buy right now: Aurora Cannabis (ACB) Source: Shutterstock Aurora Cannabis (NYSE:) recently issued its earnings results for the first quarter of 2019. Let’s just say the print wasn’t exactly great for ACB stock. With such a wide gap, conventional wisdom dictates that you shoul... |
38433.0 | 2019-05-16 00:00:00 UTC | The Most Popular Pot Stock's 3 Biggest Grow Sites Have a Common Problem | ACB | https://www.nasdaq.com/articles/most-popular-pot-stocks-3-biggest-grow-sites-have-common-problem-2019-05-16 | nan | nan | Whether you realize it or not, the marijuana industry could very well be this generation's once-in-a-lifetime investment opportunity.
Although many of the biggest brand-name companies have already appreciated by quadruple-digit percentages, the opportunity that legal cannabis presents is undeniable. Having produced les... | Aurora Cannabis has an irritating problem with its biggest grow farms Chief among these brand-name pot stocks is Aurora Cannabis (NYSE: ACB). Beyond just Aurora Sun, the most popular pot stock also has MedReleaf's 1 million-square-foot Exeter facility in its portfolio, which is capable of at least 105,000 kilos of cann... | Aurora Cannabis has an irritating problem with its biggest grow farms Chief among these brand-name pot stocks is Aurora Cannabis (NYSE: ACB). Beyond just Aurora Sun, the most popular pot stock also has MedReleaf's 1 million-square-foot Exeter facility in its portfolio, which is capable of at least 105,000 kilos of cann... | Aurora Cannabis has an irritating problem with its biggest grow farms Chief among these brand-name pot stocks is Aurora Cannabis (NYSE: ACB). Beyond just Aurora Sun, the most popular pot stock also has MedReleaf's 1 million-square-foot Exeter facility in its portfolio, which is capable of at least 105,000 kilos of cann... | Aurora Cannabis has an irritating problem with its biggest grow farms Chief among these brand-name pot stocks is Aurora Cannabis (NYSE: ACB). Then again, the more than 230,000 kilos that the company expects annually from Aurora Sun -- a healthy 142 grams per square foot, which is over 40% higher than the industry avera... |
38434.0 | 2019-05-15 00:00:00 UTC | Aurora Cannabis Inc. (ACB) Q3 2019 Earnings Call Transcript | ACB | https://www.nasdaq.com/articles/aurora-cannabis-inc.-acb-q3-2019-earnings-call-transcript-2019-05-15 | nan | nan | Image source: The Motley Fool.
Aurora Cannabis Inc. (NYSE: ACB)
Q3 2019 Earnings Call
May 15, 2019, 10:30 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning, everyone. Welcome to the Aurora Cannabis third quarter fiscal 2019 conference call for the three m... | Aurora Cannabis Inc. (NYSE: ACB) Q3 2019 Earnings Call May 15, 2019, 10:30 a.m. Duration: 90 minutes Call participants: Cam Battley -- Chief Corporate Officer Terry Booth -- Chief Executive Officer Glen Ibbott -- Chief Financial Officer Viven Azer -- Cowen and Company -- Managing Director Christopher Carey -- Bank of A... | Duration: 90 minutes Call participants: Cam Battley -- Chief Corporate Officer Terry Booth -- Chief Executive Officer Glen Ibbott -- Chief Financial Officer Viven Azer -- Cowen and Company -- Managing Director Christopher Carey -- Bank of America Merrill Lynch -- Analyst Tammy Chen -- BMO Capital Markets -- Analyst Luk... | Duration: 90 minutes Call participants: Cam Battley -- Chief Corporate Officer Terry Booth -- Chief Executive Officer Glen Ibbott -- Chief Financial Officer Viven Azer -- Cowen and Company -- Managing Director Christopher Carey -- Bank of America Merrill Lynch -- Analyst Tammy Chen -- BMO Capital Markets -- Analyst Luk... | Duration: 90 minutes Call participants: Cam Battley -- Chief Corporate Officer Terry Booth -- Chief Executive Officer Glen Ibbott -- Chief Financial Officer Viven Azer -- Cowen and Company -- Managing Director Christopher Carey -- Bank of America Merrill Lynch -- Analyst Tammy Chen -- BMO Capital Markets -- Analyst Luk... |
38435.0 | 2019-05-15 00:00:00 UTC | Aurora Cannabis Earnings: ACB Stock Gains on Wider Q3 Loss, Sales Miss | ACB | https://www.nasdaq.com/articles/aurora-cannabis-earnings%3A-acb-stock-gains-wider-q3-loss-sales-miss-2019-05-15 | nan | nan | Aurora Cannabis (NYSE:) reported its latest quarterly earnings results late today, bringing in a loss that was wider than expected and wider than it was a year ago, while revenue grew considerably, yet this amount was below Wall Street’s expectations.
The Canada-based marijuana business announced that for its third qua... | ACB stock is up roughly 3.6% following the company’s quarterly earnings results. Analysts were calling for the company to amass adjusted losses of 5 cents per share, according to data compiled by FactSet. After excluding excise taxes paid to the Canadian government, the company posted net revenue of C$65.2 million. | ACB stock is up roughly 3.6% following the company’s quarterly earnings results. Aurora Cannabis (NYSE:) reported its latest quarterly earnings results late today, bringing in a loss that was wider than expected and wider than it was a year ago, while revenue grew considerably, yet this amount was below Wall Street’s e... | ACB stock is up roughly 3.6% following the company’s quarterly earnings results. The Canada-based marijuana business announced that for its third quarter of its fiscal 2019, it brought in losses of C$160.1 million, or 16 cents per share, which was eight times as wide as the company’s year-ago losses of C$20 million, or... | ACB stock is up roughly 3.6% following the company’s quarterly earnings results. Aurora Cannabis (NYSE:) reported its latest quarterly earnings results late today, bringing in a loss that was wider than expected and wider than it was a year ago, while revenue grew considerably, yet this amount was below Wall Street’s e... |
38436.0 | 2019-05-15 00:00:00 UTC | Health Care Sector Update for 05/15/2019: ABBV,ACB,ACB.TO,ECOR,IMGN | ACB | https://www.nasdaq.com/articles/health-care-sector-update-for-05-15-2019%3A-abbvacbacb.toecorimgn-2019-05-15 | nan | nan | Top Health Care Stocks
JNJ +0.12%
PFE +1.36%
ABT +0.85%
MRK +0.39%
AMGN +1.38%
Health care stocks still were rising, with the NYSE Health Care Index adding almost 0.6% in value late Wednesday while shares of health care companies in the S&P 500 were up slightly more than 0.4% as a group. The Nasdaq Biotechnology index ... | In other sector news: (+) Aurora Cannabis (ACB) was 3% higher, turning around a 4% decline earlier in the session after the Canadian medical and recreational marijuana reported a four-fold increase in fiscal Q3 revenue, rising to CND65.1 million from CND16.1 million during the same quarter last year. Among health care ... | In other sector news: (+) Aurora Cannabis (ACB) was 3% higher, turning around a 4% decline earlier in the session after the Canadian medical and recreational marijuana reported a four-fold increase in fiscal Q3 revenue, rising to CND65.1 million from CND16.1 million during the same quarter last year. Health care stocks... | In other sector news: (+) Aurora Cannabis (ACB) was 3% higher, turning around a 4% decline earlier in the session after the Canadian medical and recreational marijuana reported a four-fold increase in fiscal Q3 revenue, rising to CND65.1 million from CND16.1 million during the same quarter last year. Health care stocks... | In other sector news: (+) Aurora Cannabis (ACB) was 3% higher, turning around a 4% decline earlier in the session after the Canadian medical and recreational marijuana reported a four-fold increase in fiscal Q3 revenue, rising to CND65.1 million from CND16.1 million during the same quarter last year. The Nasdaq Biotech... |
38437.0 | 2019-05-15 00:00:00 UTC | For Aurora Stock, The Bullish Bet Is Still On | ACB | https://www.nasdaq.com/articles/aurora-stock-bullish-bet-still-2019-05-15 | nan | nan | On Monday, when the markets were falling off a cliff from fears of the tariff war with China, the headlines were about Aurora Cannabis (NYSE:) tumbling ahead of earnings. But on Tuesday, the stock closed up 4.5% into the earnings event. This morning ACB is down 1.2% on the earnings headline, though it dipped lower earl... | This morning ACB is down 1.2% on the earnings headline, though it dipped lower earlier. Overnight, ACB reported earnings and Wall Street did not like what they saw. The sellers stepped into ACB because they missed on both the top and bottom lines. | For example Constellation Brands (NYSE:) gave $4.5 billion to TLRY and Altria (NYSE:) invested similarly in ACB. This morning ACB is down 1.2% on the earnings headline, though it dipped lower earlier. Overnight, ACB reported earnings and Wall Street did not like what they saw. | There are other micro levels but if the thesis is to own ACB stock for the long term then it’s futile to waste time dissecting the micro time frames. This morning ACB is down 1.2% on the earnings headline, though it dipped lower earlier. Overnight, ACB reported earnings and Wall Street did not like what they saw. | What Now for ACB Stock? This morning ACB is down 1.2% on the earnings headline, though it dipped lower earlier. Overnight, ACB reported earnings and Wall Street did not like what they saw. |
38438.0 | 2019-05-15 00:00:00 UTC | 5 Tremendously Important Numbers in Aurora Cannabis' Q3 Results You Might Have Overlooked | ACB | https://www.nasdaq.com/articles/5-tremendously-important-numbers-aurora-cannabis-q3-results-you-might-have-overlooked-2019 | nan | nan | Anyone thinking that Aurora Cannabis (NYSE: ACB) would slow down in the third quarter very much missed the mark. The company posted skyrocketing revenue growth that beat analysts' estimates. Aurora's fast-growing sales were enough to wipe away any worries about yet another net loss.
But while investors certainly should... | Anyone thinking that Aurora Cannabis (NYSE: ACB) would slow down in the third quarter very much missed the mark. SG&A expense growth of only 1% Yes, Aurora's net loss of CA$158.4 million looked pretty bad at first glance. But it included a CA$102 million impact from a noncash fair value loss in the company's convertibl... | Anyone thinking that Aurora Cannabis (NYSE: ACB) would slow down in the third quarter very much missed the mark. 1. International sales growth of 38% Aurora's Q3 sales of medical cannabis in international markets grew 38% over the previous quarter to 4 million Canadian dollars. Production cash cost per gram decrease of... | Anyone thinking that Aurora Cannabis (NYSE: ACB) would slow down in the third quarter very much missed the mark. 1. International sales growth of 38% Aurora's Q3 sales of medical cannabis in international markets grew 38% over the previous quarter to 4 million Canadian dollars. Production cash cost per gram decrease of... | Anyone thinking that Aurora Cannabis (NYSE: ACB) would slow down in the third quarter very much missed the mark. The company should be able to allocate more product to international markets this year, which should drive growth even higher. But the company has boosted its international extraction capacity to nearly 7,00... |
38439.0 | 2019-05-15 00:00:00 UTC | Aurora Cannabis Keeps Its Momentum Going in Q3 | ACB | https://www.nasdaq.com/articles/aurora-cannabis-keeps-its-momentum-going-q3-2019-05-15 | nan | nan | Aurora Cannabis (NYSE: ACB) has been on a roll so far in 2019. Several analysts have jumped on the Canadian marijuana stock's bandwagon, and Aurora was selected as one of only three companies to receive licenses to cultivate medical cannabis in Germany.
But the company's momentum was put to the test on Tuesday when Aur... | Aurora Cannabis (NYSE: ACB) has been on a roll so far in 2019. Several analysts have jumped on the Canadian marijuana stock's bandwagon, and Aurora was selected as one of only three companies to receive licenses to cultivate medical cannabis in Germany. But the company's momentum was put to the test on Tuesday when Aur... | Aurora Cannabis (NYSE: ACB) has been on a roll so far in 2019. The company announced a net loss in the third quarter of CA$158.4 million, or CA$0.16 per share. Aurora's bottom line improved from the second quarter net loss of CA$237.8 million but widened considerably from the net loss of CA$19.2 million reported in the... | Aurora Cannabis (NYSE: ACB) has been on a roll so far in 2019. The company announced a net loss in the third quarter of CA$158.4 million, or CA$0.16 per share. Aurora's bottom line improved from the second quarter net loss of CA$237.8 million but widened considerably from the net loss of CA$19.2 million reported in the... | Aurora Cannabis (NYSE: ACB) has been on a roll so far in 2019. The company announced a net loss in the third quarter of CA$158.4 million, or CA$0.16 per share. The company reported medical cannabis net revenue of CA$29.1 million, a year-over-year increase of 169% and a quarter-over-quarter increase of 12%. |
38440.0 | 2019-05-15 00:00:00 UTC | The 10 Most Important Numbers in Aurora Cannabis' Third-Quarter Report | ACB | https://www.nasdaq.com/articles/10-most-important-numbers-aurora-cannabis-third-quarter-report-2019-05-15 | nan | nan | Earnings season is in full swing, and in case you weren't aware, that includes marijuana stocks. In recent days, the latest quarterly results have been reported for a number of the largest cannabis growers in our neighbor to the north, including what's arguably the most popular pot stock on the planet, Aurora Cannabis ... | In recent days, the latest quarterly results have been reported for a number of the largest cannabis growers in our neighbor to the north, including what's arguably the most popular pot stock on the planet, Aurora Cannabis (NYSE: ACB). A little more than a week ago, I recounted the 10 most important numbers that Wall S... | In recent days, the latest quarterly results have been reported for a number of the largest cannabis growers in our neighbor to the north, including what's arguably the most popular pot stock on the planet, Aurora Cannabis (NYSE: ACB). Aurora logged CA$29.6 million in adult-use sales in Q3 2019, representing a 37% sequ... | In recent days, the latest quarterly results have been reported for a number of the largest cannabis growers in our neighbor to the north, including what's arguably the most popular pot stock on the planet, Aurora Cannabis (NYSE: ACB). Gross or net revenue: CA$75.2 million/CA$65.1 million Probably the headline of Auror... | In recent days, the latest quarterly results have been reported for a number of the largest cannabis growers in our neighbor to the north, including what's arguably the most popular pot stock on the planet, Aurora Cannabis (NYSE: ACB). Aurora logged CA$29.6 million in adult-use sales in Q3 2019, representing a 37% sequ... |
38441.0 | 2019-05-14 00:00:00 UTC | There’s a Pretty Strong Speculative Case for Buying Aphria Stock | ACB | https://www.nasdaq.com/articles/theres-pretty-strong-speculative-case-buying-aphria-stock-2019-05-14 | nan | nan | Amid a disappointing earnings report, Aphria (NYSE:) continues on the path to recovery. Allegations regarding an asset purchase and conflicts of interest in the C suite sent Aphria stock from over $16 per share to under $4 per share for a brief time.
Source: Shutterstock
However, a new CEO has restored some confidence ... | A Closer Look at Aphria Fast forward to today, and both CEO Vic Neufeld and co-founder and Cole Cacciavillani have left the company. Further, a review of the purchase determined that Aphria paid a high but acceptable price for legitimate assets in Latin America. Thanks in part to the lower stock price, the company find... | Allegations regarding an asset purchase and conflicts of interest in the C suite sent Aphria stock from over $16 per share to under $4 per share for a brief time. However, it holds the holdings in Latin America which caused issues for the company last year. Thanks in part to the lower stock price, the company finds its... | Allegations regarding an asset purchase and conflicts of interest in the C suite sent Aphria stock from over $16 per share to under $4 per share for a brief time. This should bring significant growth for APHA even if they never enter the U.S. Bottom Line on Aphria Stock Now that the company has put conflicts of interes... | Aphria stock trades at a forward price-to-earnings (PE) ratio of 22.9. Yes, it recently divested its U.S. assets. Regardless of whether owners of APHA benefit from profit growth or a buyout, the future again appears bright for Aphria stock. |
38442.0 | 2019-05-14 00:00:00 UTC | Canopy Growth Stock Is a Good Buy Even If the Acreage Deal Collapses | ACB | https://www.nasdaq.com/articles/canopy-growth-stock-good-buy-even-if-acreage-deal-collapses-2019-05-14 | nan | nan | Canopy Growth (NYSE:) has big plans, if they come too much under fire, though, it could hurt Canopy Growth stock.
Source: Shutterstock
When it comes to the cannabis opportunity, a key strategy for the large operators is M&A (Mergers & Acquisitions). This makes a lot of sense as scale will likely be the critical factor ... | Source: Shutterstock When it comes to the cannabis opportunity, a key strategy for the large operators is M&A (Mergers & Acquisitions). The letter to the board did not mince words, saying the deal is “value destroying.” Interestingly enough, it points out the divergence in the reaction from Wall Street. According to th... | But one important shareholder, Marcato Capital Management, of ACRGF is far from satisfied. Bottom Line on Canopy Growth Stock For CGC stock, I think the deal for ACRGF is spot-on and is structured right. In the meantime, Canopy Growth stock is still positioned nicely to grow even without the deal. | According to the : “In total, Canopy’s market capitalization has increased by roughly US $3.5 billion since the deal announcement, indicating pro forma economic value to Canopy of US $6.9 billion — over 100% greater than the price offered to Acreage shareholders.” The letter also notes other issues: the uncertainty of ... | Although, perhaps the most important factor is that organic growth is often just too slow. But one important shareholder, Marcato Capital Management, of ACRGF is far from satisfied. In the meantime, Canopy Growth stock is still positioned nicely to grow even without the deal. |
38443.0 | 2019-05-14 00:00:00 UTC | If Aurora Stock Falls on Earnings, Buy the Dip | ACB | https://www.nasdaq.com/articles/if-aurora-stock-falls-earnings-buy-dip-2019-05-14 | nan | nan | Canadian cannabis giant Aurora (NYSE:) is set to report third-quarter earnings after the bell on Tuesday. Investors shouldn’t get too excited about the report. Long story short, pot sales appear to have stagnated in Canada in the early part of 2019, mostly due to demand confusion and supply shortages, and affecting mar... | Thus, Aurora’s numbers likely won’t be all that great, and ACB stock could drop in response. Zooming out, the long-term growth fundamentals supporting ACB stock are healthy, and the valuation underlying the stock is very attractive relative to its marijuana stock peers. In other words, when it comes to ACB stock, it’s ... | Bottom Line on ACB Stock Aurora’s third-quarter numbers likely won’t be great, and ACB stock could fall in response. Thus, Aurora’s numbers likely won’t be all that great, and ACB stock could drop in response. Zooming out, the long-term growth fundamentals supporting ACB stock are healthy, and the valuation underlying ... | In other words, when it comes to ACB stock, it’s all about the big picture, and a quarterly earnings report just a few months into Canadian cannabis market legalization isn’t a big deal in that big picture. Bottom Line on ACB Stock Aurora’s third-quarter numbers likely won’t be great, and ACB stock could fall in respon... | The Quarter Will Be Mixed for ACB Stock Aurora’s third quarter numbers likely won’t be that great. Investors won’t be too impressed with the slowing growth part, and ACB stock could fall in response. Thus, Aurora’s numbers likely won’t be all that great, and ACB stock could drop in response. |
38444.0 | 2019-05-13 00:00:00 UTC | 3 Things You Can Expect with Aurora Cannabis' Q3 Earnings | ACB | https://www.nasdaq.com/articles/3-things-you-can-expect-aurora-cannabis-q3-earnings-2019-05-13 | nan | nan | There weren't any real surprises when Aurora Cannabis (NYSE: ACB) announced its fiscal 2019 second-quarter earnings results in February. That's mainly because the Canadian marijuana producer provided a sneak peek of what its Q2 results would look like a month earlier.
Aurora is scheduled to report its third-quarter ear... | There weren't any real surprises when Aurora Cannabis (NYSE: ACB) announced its fiscal 2019 second-quarter earnings results in February. Strong revenue growth Scotiabank analysts Oliver Rowe and Ben Isaacson say that the Canadian cannabis industry is experiencing "teething pains" that could weigh on the sales of major ... | There weren't any real surprises when Aurora Cannabis (NYSE: ACB) announced its fiscal 2019 second-quarter earnings results in February. But you can expect Aurora to report strong revenue growth in Q3, probably in the ballpark of $68 million Canadian ($50.7 million). An improving bottom line Aurora posted an ugly net l... | There weren't any real surprises when Aurora Cannabis (NYSE: ACB) announced its fiscal 2019 second-quarter earnings results in February. But you can expect Aurora to report strong revenue growth in Q3, probably in the ballpark of $68 million Canadian ($50.7 million). Even with the company continuing to burn through cas... | There weren't any real surprises when Aurora Cannabis (NYSE: ACB) announced its fiscal 2019 second-quarter earnings results in February. He didn't provide any details but did state that "we certainly haven't slowed down at all in terms of our production and shipments." What not to expect It's probably too soon for inve... |
38445.0 | 2019-05-13 00:00:00 UTC | Charts Indicate That the Risk/Reward Ratio of Cronos Stock Is Reasonable | ACB | https://www.nasdaq.com/articles/charts-indicate-risk/reward-ratio-cronos-stock-reasonable-2019-05-13 | nan | nan | Cronos (NASDAQ:) stock dropped almost 10% on Thursday after the company’s fiscal first-quarter results were released. For those who regularly trade CRON stock, the decline was not surprising. Nor was the bounce of CRON stock on Friday. CRON stock remains locked in a downtrend.
Is now the time for long-term bulls to buy... | It helps that the downtrend support of Cronos Group stock is coming into the picture around current levels and that the 200-day moving average sits at $13.28. The Bottom Line on Cronos Group Stock (Note: the below figures are in Canadian dollars) In Q1, CRON churned out a GAAP profit of 42 cents on revenue that grew 1... | Trading CRON Stock It’s clear that $24-$25 is resistance on the chart, while CRON stock is locked in a violent downtrend. It helps that the downtrend support of Cronos Group stock is coming into the picture around current levels and that the 200-day moving average sits at $13.28. The point is that many investors — fro... | Trading CRON Stock It’s clear that $24-$25 is resistance on the chart, while CRON stock is locked in a violent downtrend. The 21-day moving average is around the same area as its downtrend resistance, so I would expect CRON stock to fail to hold that level. It helps that the downtrend support of Cronos Group stock is ... | That said, some think that CRON stock has potential, so let’s take a look. Trading CRON Stock It’s clear that $24-$25 is resistance on the chart, while CRON stock is locked in a violent downtrend. It helps that the downtrend support of Cronos Group stock is coming into the picture around current levels and that the 20... |
38446.0 | 2019-05-13 00:00:00 UTC | Oversold Conditions For Aurora Cannabis (ACB) | ACB | https://www.nasdaq.com/articles/oversold-conditions-aurora-cannabis-acb-2019-05-13 | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.... | In trading on Monday, shares of Aurora Cannabis Inc (Symbol: ACB) entered into oversold territory, hitting an RSI reading of 28.8, after changing hands as low as $7.92 per share. A bullish investor could look at ACB's 28.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself,... | A bullish investor could look at ACB's 28.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACB shares: Looking at the chart above, ACB's low point in its ... | In trading on Monday, shares of Aurora Cannabis Inc (Symbol: ACB) entered into oversold territory, hitting an RSI reading of 28.8, after changing hands as low as $7.92 per share. A bullish investor could look at ACB's 28.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself,... | In trading on Monday, shares of Aurora Cannabis Inc (Symbol: ACB) entered into oversold territory, hitting an RSI reading of 28.8, after changing hands as low as $7.92 per share. A bullish investor could look at ACB's 28.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself,... |
38447.0 | 2019-05-13 00:00:00 UTC | Cronos Group Wraps Up Another Laughably Bad Quarter | ACB | https://www.nasdaq.com/articles/cronos-group-wraps-another-laughably-bad-quarter-2019-05-13 | nan | nan | If you think the broad-based S&P 500 is having itself an incredible year, then you probably haven't been paying close enough attention to the marijuana industry. The very first cannabis exchange-traded fund, the Horizons Marijuana Life Sciences ETF, has practically tripled the return of the S&P 500 since the year began... | Secondly, Cronos Group recorded a gain of CA$20.6 million on the sale of its stake in Whistler Medical Marijuana to Aurora Cannabis (NYSE: ACB). This platform is expected to produce yeast strains that can yield desired cannabinoids at commercial scale, and for a low cost, relative to traditional extraction techniques. ... | Secondly, Cronos Group recorded a gain of CA$20.6 million on the sale of its stake in Whistler Medical Marijuana to Aurora Cannabis (NYSE: ACB). In the first quarter, Cronos Group netted a total positive fair value adjustment of CA$9.83 million. And if we're talking about sheer volume of cannabis sales, the Pure Sunfar... | Secondly, Cronos Group recorded a gain of CA$20.6 million on the sale of its stake in Whistler Medical Marijuana to Aurora Cannabis (NYSE: ACB). For the quarter, Cronos Group generated $6.47 million Canadian in net sales ($4.81 million), a 120% year-over-year increase from the first quarter of 2018, with CA$6.99 millio... | Secondly, Cronos Group recorded a gain of CA$20.6 million on the sale of its stake in Whistler Medical Marijuana to Aurora Cannabis (NYSE: ACB). In the first quarter, Cronos Group netted a total positive fair value adjustment of CA$9.83 million. See the 10 stocks *Stock Advisor returns as of March 1, 2019 Sean Williams... |
38448.0 | 2019-05-13 00:00:00 UTC | This Partnership with EnWave Means Great Things for Aurora Stock | ACB | https://www.nasdaq.com/articles/partnership-enwave-means-great-things-aurora-stock-2019-05-13 | nan | nan | A couple of weeks ago, I covered the odor problems Edmonton-based Aurora Cannabis (NYSE:) was having at its Aurora Sky grow op near the city’s airport. You wouldn’t think this kind of issue would be good for Aurora stock, but that’s precisely what I argued.
Source: Shutterstock
The is the real deal.
As a result of my ... | Under the terms of the agreement, Aurora gains the exclusive rights to the patented REV drying technology for use in the production of cannabis in the European Union excluding Portugal. Considering flavor is a crucial component of a marijuana user’s experience, being able to retain this through the drying process is an... | As part of this agreement, Aurora is buying two of EnWave’s 120kW REV dehydration systems for both its Aurora Sky and Aurora Sun facilities with plans to purchase a third unit for its Aurora Nordic facility in Denmark. Aurora and EnWave will work together to jointly benefit from the REV technology making its way throug... | Aurora Gets Exclusive On April 26, Aurora announced that it had entered into a royalty-bearing commercial license agreement with Vancouver-based Enwave Corporation (OTCMKTS:), a provider of Radiant Energy Vacuum (REV) technology for the dehydration of organic materials. As part of this agreement, Aurora is buying two o... | Under the terms of the agreement, Aurora gains the exclusive rights to the patented REV drying technology for use in the production of cannabis in the European Union excluding Portugal. Aurora and EnWave will work together to jointly benefit from the REV technology making its way through the cannabis industry. EnWave a... |
38449.0 | 2019-05-12 00:00:00 UTC | Is Aurora Cannabis' Partnering Strategy Brilliant or Boneheaded? | ACB | https://www.nasdaq.com/articles/aurora-cannabis-partnering-strategy-brilliant-or-boneheaded-2019-05-12 | nan | nan | Don't expect Aurora Cannabis (NYSE: ACB) to receive a huge investment from a big company outside the cannabis industry. There aren't likely to be high-dollar transactions like Canopy Growth (NYSE: CGC) or Cronos Group (NASDAQ: CRON) had. There's a simple reason: Aurora doesn't want that kind of a deal.
Aurora's chief c... | Don't expect Aurora Cannabis (NYSE: ACB) to receive a huge investment from a big company outside the cannabis industry. Aurora's chief corporate officer stated in an interview with MarketWatch earlier this month that the company is "taking a different approach" to partnering outside of the cannabis industry than some o... | Don't expect Aurora Cannabis (NYSE: ACB) to receive a huge investment from a big company outside the cannabis industry. Aurora isn't the only major Canadian cannabis company employing this partnering strategy. The company has already teamed up with partners in several industries: big drugmaker Novartis, giant beer make... | Don't expect Aurora Cannabis (NYSE: ACB) to receive a huge investment from a big company outside the cannabis industry. And instead of teaming up with just one big company outside of the cannabis industry, he advised Aurora to seek multiple partners across several industries that could be disrupted by cannabis. Aurora ... | Don't expect Aurora Cannabis (NYSE: ACB) to receive a huge investment from a big company outside the cannabis industry. Aurora isn't the only major Canadian cannabis company employing this partnering strategy. Another drawback to Aurora's partnering approach is that it won't have the huge infusion of cash that comes wi... |
38450.0 | 2019-05-12 00:00:00 UTC | Writedowns Are Likely for These 3 Marijuana Stocks | ACB | https://www.nasdaq.com/articles/writedowns-are-likely-these-3-marijuana-stocks-2019-05-12 | nan | nan | The marijuana industry is looking like it could be one of the greatest growth stories of our generation. Having long existed behind the scenes in the black market, the now-legal pot industry is budding, and it has quite the audience in Wall Street.
Last year, the global legal cannabis industry generated $12.2 billion i... | Aurora Cannabis Aurora Cannabis (NYSE: ACB), Canada's projected leading pot producer, looks to have one of the highest probabilities of taking a writedown among all marijuana stocks. We've witnessed about a half-dozen major acquisitions among vertically integrated dispensary operators in the U.S. since October, as well... | Aurora Cannabis Aurora Cannabis (NYSE: ACB), Canada's projected leading pot producer, looks to have one of the highest probabilities of taking a writedown among all marijuana stocks. The company ended the fiscal second quarter (Dec. 31, 2018) with CA$3.06 billion in goodwill on its balance sheet, representing 63% of th... | Aurora Cannabis Aurora Cannabis (NYSE: ACB), Canada's projected leading pot producer, looks to have one of the highest probabilities of taking a writedown among all marijuana stocks. Depending on your preferred Wall Street investment firm, the legal pot industry is capable of between $50 billion and $75 billion in worl... | Aurora Cannabis Aurora Cannabis (NYSE: ACB), Canada's projected leading pot producer, looks to have one of the highest probabilities of taking a writedown among all marijuana stocks. The company ended the fiscal second quarter (Dec. 31, 2018) with CA$3.06 billion in goodwill on its balance sheet, representing 63% of th... |
38451.0 | 2019-05-10 00:00:00 UTC | Aurora Cannabis Earnings Need to Tell a Better Story | ACB | https://www.nasdaq.com/articles/aurora-cannabis-earnings-need-tell-better-story-2019-05-10 | nan | nan | It appears that marijuana stocks like Aurora Cannabis (NYSE:) are headed towards a crossroad. The optimism toward the sector is obvious and logical, but it has already led to huge gains in Aurora Cannabis stock. The stock has gained 44% in 2019 alone, and it is up 68% over the past year.
Source: Shutterstock
That said,... | ACB stock has pulled back in recent sessions, as has the most valuable company in the industry, Canopy Growth (NYSE:). Strong earnings — and perhaps more importantly, positive commentary from management — could go a long way toward validating that strategy and creating a more solid base for ACB stock and perhaps the in... | From here, it seems like it will take a big report from Aurora to move both ACB stock and other pot plays higher. ACB stock has pulled back in recent sessions, as has the most valuable company in the industry, Canopy Growth (NYSE:). Strong earnings — and perhaps more importantly, positive commentary from management — c... | ACB Stock Pulls Back It’s not hard to see some cracks in the story surrounding marijuana stocks on the whole, and Aurora Cannabis stock in particular. ACB stock has pulled back in recent sessions, as has the most valuable company in the industry, Canopy Growth (NYSE:). Strong earnings — and perhaps more importantly, po... | ACB Stock Pulls Back It’s not hard to see some cracks in the story surrounding marijuana stocks on the whole, and Aurora Cannabis stock in particular. ACB stock has pulled back in recent sessions, as has the most valuable company in the industry, Canopy Growth (NYSE:). Strong earnings — and perhaps more importantly, po... |
38452.0 | 2019-05-10 00:00:00 UTC | It Makes Sense to Lay off Aurora Stock Ahead of Next Week’s Earnings | ACB | https://www.nasdaq.com/articles/it-makes-sense-lay-aurora-stock-ahead-next-weeks-earnings-2019-05-10 | nan | nan | Since late March, Aurora Cannabis (NYSE:) stock has been in a fairly tight trading range. But next Tuesday we may see some action. Yes, the company will report its fiscal third quarter results. No doubt, it will be a critical, as investors will want to get a sense of how the Canadian recreational market is tracking, an... | Here’s a look: Bottom Line on ACB Stock When it comes to ACB stock, there are both short-term and long-term tailwinds. As for the long-term catalysts for ACB stock, there is the medical business. But there is another key factor for ACB stock: The company has appointed Nelson Peltz as a Strategic Advisor. | In other words, Nelson will likely be critical in helping ACB find major strategic partners to help propel the growth, similar to what other cannabis firms like Canopy Growth (NYSE:) and Cronos have done. Here’s a look: Bottom Line on ACB Stock When it comes to ACB stock, there are both short-term and long-term tailwin... | In other words, Nelson will likely be critical in helping ACB find major strategic partners to help propel the growth, similar to what other cannabis firms like Canopy Growth (NYSE:) and Cronos have done. Here’s a look: Bottom Line on ACB Stock When it comes to ACB stock, there are both short-term and long-term tailwin... | In other words, Nelson will likely be critical in helping ACB find major strategic partners to help propel the growth, similar to what other cannabis firms like Canopy Growth (NYSE:) and Cronos have done. Here’s a look: Bottom Line on ACB Stock When it comes to ACB stock, there are both short-term and long-term tailwin... |
38453.0 | 2019-05-09 00:00:00 UTC | Why Tilray Stock Could Be the Best Pick Among Marijuana Names | ACB | https://www.nasdaq.com/articles/why-tilray-stock-could-be-best-pick-among-marijuana-names-2019-05-09 | nan | nan | From one perspective, Tilray (NASDAQ:) looks like a massive disappointment. Most marijuana stocks have performed nicely this year, but Tilray stock hasn’t followed that trend. TLRY stock price is down 34% so far this year. And it’s lost a full 85% from its 52-week high.
In the context of the industry, that performance... | In the meantime, as InvestorPlace columnist Tom Taulli pointed out, Tilray, unlike Cronos and Canopy, to bring in cash and/or a partner with consumer expertise. Rather, its management simply sees the Canadian marijuana market heading toward a period of oversupply and doesn’t want to throw good money after bad. If a s... | And with Constellation Brands (NYSE:,STZ.B) and Altria (NYSE:) putting billions into Canopy and Cronos, respectively, there is a clear long-term risk that Tilray stock will get left behind. Why TLRY Stock Price Has Lagged Other Marijuana Stocks At this point, marijuana stocks still are priced based on feelings. Plungi... | But Tilray’s intriguing strategy means Tilray stock might not be as far behind as the stock charts seem to imply. Why TLRY Stock Price Has Lagged Other Marijuana Stocks At this point, marijuana stocks still are priced based on feelings. (That stake has caused the number of shares of TLRY stock to be quite limited and ... | TLRY stock price is down 34% so far this year. Why TLRY Stock Price Has Lagged Other Marijuana Stocks At this point, marijuana stocks still are priced based on feelings. (That stake has caused the number of shares of TLRY stock to be quite limited and is part of the reason TLRY stock price went so crazy last year.) |
38454.0 | 2019-05-08 00:00:00 UTC | 3 Things to Consider About Aurora Cannabis Stock Ahead of Q3 | ACB | https://www.nasdaq.com/articles/3-things-consider-about-aurora-cannabis-stock-ahead-q3-2019-05-08 | nan | nan | Right now, nothing in the “regular” markets generates as much buzz as marijuana stocks. That’s not going to change any time soon, with Aurora Cannabis (NYSE:) scheduled to release its third quarter of fiscal 2019 earnings results next week. As one of the leading names in the weed industry, many eyes will focus on ACB s... | As one of the leading names in the weed industry, many eyes will focus on ACB stock. Clearly, Aurora Cannabis has an opportunity to swing ACB stock sharply in either direction. Here are three factors to consider ahead of Q3 earnings: Medical Cannabis Boosts Profile for ACB Stock If you ever get a chance to sit down wit... | As one of the leading names in the weed industry, many eyes will focus on ACB stock. Clearly, Aurora Cannabis has an opportunity to swing ACB stock sharply in either direction. Here are three factors to consider ahead of Q3 earnings: Medical Cannabis Boosts Profile for ACB Stock If you ever get a chance to sit down wit... | Here are three factors to consider ahead of Q3 earnings: Medical Cannabis Boosts Profile for ACB Stock If you ever get a chance to sit down with Aurora’s management team, chances are, they’ll tell you this: ACB stock is first and foremost a medical-marijuana investment. As one of the leading names in the weed industry,... | As one of the leading names in the weed industry, many eyes will focus on ACB stock. Clearly, Aurora Cannabis has an opportunity to swing ACB stock sharply in either direction. Here are three factors to consider ahead of Q3 earnings: Medical Cannabis Boosts Profile for ACB Stock If you ever get a chance to sit down wit... |
38455.0 | 2019-05-07 00:00:00 UTC | 10 Numbers to Focus On When Aurora Cannabis Reports Its Third-Quarter Results | ACB | https://www.nasdaq.com/articles/10-numbers-focus-when-aurora-cannabis-reports-its-third-quarter-results-2019-05-07 | nan | nan | It's that time again, folks. Next week, Aurora Cannabis (NYSE: ACB), the most popular pot stock among millennials and a very polarizing stock as a whole, is slated to report its fiscal third-quarter earnings, which covers the period from Jan. 1, 2019, through March 31, 2019.
As the second-largest marijuana stock by mar... | Next week, Aurora Cannabis (NYSE: ACB), the most popular pot stock among millennials and a very polarizing stock as a whole, is slated to report its fiscal third-quarter earnings, which covers the period from Jan. 1, 2019, through March 31, 2019. Recreational-to-medical sales ratio In case you missed it, Aurora Cannabi... | Next week, Aurora Cannabis (NYSE: ACB), the most popular pot stock among millennials and a very polarizing stock as a whole, is slated to report its fiscal third-quarter earnings, which covers the period from Jan. 1, 2019, through March 31, 2019. Although gross or net revenue (net revenue is simply gross cannabis sales... | Next week, Aurora Cannabis (NYSE: ACB), the most popular pot stock among millennials and a very polarizing stock as a whole, is slated to report its fiscal third-quarter earnings, which covers the period from Jan. 1, 2019, through March 31, 2019. Although gross or net revenue (net revenue is simply gross cannabis sales... | Next week, Aurora Cannabis (NYSE: ACB), the most popular pot stock among millennials and a very polarizing stock as a whole, is slated to report its fiscal third-quarter earnings, which covers the period from Jan. 1, 2019, through March 31, 2019. Instead, pay close attention to the company's operating loss to see if it... |
38456.0 | 2019-05-07 00:00:00 UTC | Hexo Stock Has Profit Potential That Just Can’t Be Ignored | ACB | https://www.nasdaq.com/articles/hexo-stock-has-profit-potential-just-cant-be-ignored-2019-05-07 | nan | nan | Hexo (NYSEAmerican:) continues to gain more attention among traders. Its position in Quebec, a major buyout, and an alliance with a key beverage firm provide a solid base that bolsters Hexo stock.
Source: Shutterstock
A low valuation compared to its peers also makes it attractive. Despite its relatively small size, HEX... | Its position in Quebec, a major buyout, and an alliance with a key beverage firm provide a solid base that bolsters Hexo stock. However, Hexo seemingly escaped the same downward trend when a Bank of America (NYSE:) analyst initiated coverage with a $10 per share price target. A deal with Molson Coors as well its purcha... | Its position in Quebec, a major buyout, and an alliance with a key beverage firm provide a solid base that bolsters Hexo stock. Alliances and Valuation Furthermore, like firms such as Canopy Growth, Cronos Group (NASDAQ:), and Tilray (NASDAQ:), Hexo stock has also attracted interest from a large, U.S.-based investor. T... | With a market cap of only $1.6 billion, this will not place Hexo stock on par with Canopy Growth (NYSE:) and Aurora Cannabis (NYSE:). Alliances and Valuation Furthermore, like firms such as Canopy Growth, Cronos Group (NASDAQ:), and Tilray (NASDAQ:), Hexo stock has also attracted interest from a large, U.S.-based inves... | Its position in Quebec, a major buyout, and an alliance with a key beverage firm provide a solid base that bolsters Hexo stock. Analysts and Hexo Stock It also has appeared to surpass the company I saw as another up-and-comer, CannTrust Holdings (NYSE:). Alliances and Valuation Furthermore, like firms such as Canopy Gr... |
38457.0 | 2019-05-06 00:00:00 UTC | 2 Marijuana Stocks to Buy Despite Declining Canadian Sales | ACB | https://www.nasdaq.com/articles/2-marijuana-stocks-buy-despite-declining-canadian-sales-2019-05-06 | nan | nan | Investors betting on marijuana stocks got some disappointing news out of Canada last week. Statistics Canada reported that Canadian marijuana retail sales declined by 7% in February compared to January.
Source: Shutterstock
On the surface, that decline may seem troubling, but it’s not actually as bad as it seems. There... | Consolidation Ahead The drop in Canadian retail sales in February underscores just how critical the marijuana supply issue is. In late April, Canopy announced a $3.4 billion conditional buyout of U.S. marijuana producer Acreage Holdings (OTCMKTS:). Bank of America analyst Christopher Carey says investors can expect ple... | In late April, Canopy announced a $3.4 billion conditional buyout of U.S. marijuana producer Acreage Holdings (OTCMKTS:). Bank of America analyst Christopher Carey says investors can expect plenty more buyout deals ahead for marijuana stocks like Canopy. Potential Seller: Hexo In addition to the best potential marijuan... | “We think Canopy showed that there are many options for Canadian marijuana companies to create value, and with Canada supply chain constraints likely to sustain near-term, we see potential that more deals are announced, potentially in the US, in the coming months,” Carey says. Potential Seller: Hexo In addition to the ... | Carey says Hexo is relatively low-risk as far as Canadian marijuana stocks go. First, Carey says HEXO stock is a rare value among marijuana stocks. The long-term winners of this consolidation will be potential buyers like CGC stock and potential sellers like HEXO stock. |
38458.0 | 2019-05-05 00:00:00 UTC | Why This Little-Known Marijuana Stock Soared 25% in April | ACB | https://www.nasdaq.com/articles/why-little-known-marijuana-stock-soared-25-april-2019-05-05 | nan | nan | What happened
Shares of EnWave (NASDAQOTH: NWVCF)(TSXV: ENW) gained 25.4% in April, according to data from S&P Global Market Intelligence. The S&P 500 (including dividends) returned 4.1% last month.
EnWave is a fast-growing small Canadian company that produces and distributes all-natural dried cheese snacks and license... | So what The main catalyst for EnWave stock's pop last month was the company's announcement on April 26 that it entered into a licensing deal and formed an intellectual-property partnership with Aurora Cannabis (NYSE: ACB), one of the top Canadian marijuana growers. EnWave is a fast-growing small Canadian company that p... | So what The main catalyst for EnWave stock's pop last month was the company's announcement on April 26 that it entered into a licensing deal and formed an intellectual-property partnership with Aurora Cannabis (NYSE: ACB), one of the top Canadian marijuana growers. The royalty-bearing license agreement gives Aurora the... | So what The main catalyst for EnWave stock's pop last month was the company's announcement on April 26 that it entered into a licensing deal and formed an intellectual-property partnership with Aurora Cannabis (NYSE: ACB), one of the top Canadian marijuana growers. Canadian grower Tilray (NASDAQ: TLRY) has the exclusiv... | So what The main catalyst for EnWave stock's pop last month was the company's announcement on April 26 that it entered into a licensing deal and formed an intellectual-property partnership with Aurora Cannabis (NYSE: ACB), one of the top Canadian marijuana growers. EnWave stock's robust April performance is a continuat... |
38459.0 | 2019-05-05 00:00:00 UTC | Aurora Cannabis' Backdoor Strategy for Entering the U.S. Market | ACB | https://www.nasdaq.com/articles/aurora-cannabis-backdoor-strategy-entering-u.s.-market-2019-05-05 | nan | nan | Aurora Cannabis' (NYSE: ACB) growing cannabis empire spans five continents. The company operates in two dozen countries. But the U.S. isn't one of them.
The problem with Aurora's lack of a U.S. presence is straightforward. Currently, nearly 80% of the world's total legal marijuana sales are made in the United States. T... | Aurora Cannabis' (NYSE: ACB) growing cannabis empire spans five continents. In January, it invested $3 million in Folium Biosciences, the largest vertically integrated producer, manufacturer, and distributor of hemp-derived phytocannabinoids in the United States. So far, though, Aurora hasn't given any hints that it mi... | Aurora Cannabis' (NYSE: ACB) growing cannabis empire spans five continents. As long as marijuana remains illegal at the federal level in the U.S., Aurora can't expand into the U.S. marijuana market and retain its stock listings on the New York Stock Exchange (NYSE) and Toronto Stock Exchange (TSX). The two warrants com... | Aurora Cannabis' (NYSE: ACB) growing cannabis empire spans five continents. As long as marijuana remains illegal at the federal level in the U.S., Aurora can't expand into the U.S. marijuana market and retain its stock listings on the New York Stock Exchange (NYSE) and Toronto Stock Exchange (TSX). However, the company... | Aurora Cannabis' (NYSE: ACB) growing cannabis empire spans five continents. Australis Capital has already expanded into the U.S. hemp market. But what about Aurora? |
38460.0 | 2019-05-05 00:00:00 UTC | Better Cannabis Stock: Aurora Cannabis vs. Charlotte's Web Holdings | ACB | https://www.nasdaq.com/articles/better-cannabis-stock%3A-aurora-cannabis-vs.-charlottes-web-holdings-2019-05-05 | nan | nan | Aurora Cannabis (NYSE: ACB) and Charlotte's Web Holdings (NASDAQOTH: CWBHF) rank as two of the hottest stocks in the cannabis industry so far in 2019. Aurora is up more than 70% year to date, while Charlotte's Web shares have gained more than 65%.
But which of these two cannabis stocks is the better pick for investors ... | Aurora Cannabis (NYSE: ACB) and Charlotte's Web Holdings (NASDAQOTH: CWBHF) rank as two of the hottest stocks in the cannabis industry so far in 2019. That's the amount of annual global marijuana sales that Bank of America analyst Christopher Carey projects could be attainable in the future. It's possible that the U.S.... | Aurora Cannabis (NYSE: ACB) and Charlotte's Web Holdings (NASDAQOTH: CWBHF) rank as two of the hottest stocks in the cannabis industry so far in 2019. That's the amount of annual global marijuana sales that Bank of America analyst Christopher Carey projects could be attainable in the future. The case for Charlotte's We... | Aurora Cannabis (NYSE: ACB) and Charlotte's Web Holdings (NASDAQOTH: CWBHF) rank as two of the hottest stocks in the cannabis industry so far in 2019. Better cannabis stock You might look at these two companies' market caps and projected total addressable market sizes and conclude that Aurora is the clear winner. Auror... | Aurora Cannabis (NYSE: ACB) and Charlotte's Web Holdings (NASDAQOTH: CWBHF) rank as two of the hottest stocks in the cannabis industry so far in 2019. The company is already considering how it might enter the U.S. hemp market now that hemp is legal throughout the United States. The case for Charlotte's Web Holdings Cha... |
38461.0 | 2019-05-05 00:00:00 UTC | These 5 Pot Stocks Have the Most Cash | ACB | https://www.nasdaq.com/articles/these-5-pot-stocks-have-most-cash-2019-05-05 | nan | nan | In case you haven't been paying attention, the marijuana industry is turning into a big business before our eyes. Once peddling a taboo product, the legal marijuana industry generated $12.2 billion in sales globally in 2018, and looks to be on track to grow sales by another 38% in 2019 to $16.9 billion. That's accordin... | Aurora Cannabis: $379 million Lastly, Canada's largest projected marijuana producer, Aurora Cannabis (NYSE: ACB), rounds out the list with approximately $379 million in its coffers. Also, last month, it announced the $3.4 billion cash-and-stock buyout of vertically integrated dispensary operator Acreage Holdings, which... | Aurora Cannabis: $379 million Lastly, Canada's largest projected marijuana producer, Aurora Cannabis (NYSE: ACB), rounds out the list with approximately $379 million in its coffers. Cronos Group: $1.82 billion The only other pot stock with more than $1 billion of cash and cash equivalents in its coffers is Cronos Group... | Aurora Cannabis: $379 million Lastly, Canada's largest projected marijuana producer, Aurora Cannabis (NYSE: ACB), rounds out the list with approximately $379 million in its coffers. Canopy Growth: $3.67 billion This should come as little surprise, but Canopy Growth (NYSE: CGC), the largest marijuana stock in the world ... | Aurora Cannabis: $379 million Lastly, Canada's largest projected marijuana producer, Aurora Cannabis (NYSE: ACB), rounds out the list with approximately $379 million in its coffers. When it comes to the green -- cash, that is -- no pot stocks have more cash on hand right now than these five. Canopy Growth: $3.67 billio... |
38462.0 | 2019-05-04 00:00:00 UTC | This Is the Single Most Important Statement Made by a Marijuana Stock Executive All Year | ACB | https://www.nasdaq.com/articles/single-most-important-statement-made-marijuana-stock-executive-all-year-2019-05-04 | nan | nan | There's arguably no hotter investment opportunity at the moment than marijuana. If you thought the 17% return of the S&P 500 through the first four months of the year was impressive, then you've obviously not been following the very first cannabis exchange-traded fund, the Horizons Marijuana Life Sciences ETF, which ha... | For example, the largest marijuana producer in Canada, Aurora Cannabis (NYSE: ACB), has made clear that its focus will be on the medical marijuana community. That's because every cannabis executive who comments on their company more or less delivers the same optimistic spiel, making it difficult for investors to read b... | For example, the largest marijuana producer in Canada, Aurora Cannabis (NYSE: ACB), has made clear that its focus will be on the medical marijuana community. Likewise, the largest marijuana stock in the world by market cap, Canopy Growth (NYSE: CGC), is also ensuring that it has a diverse product portfolio. Also, with ... | For example, the largest marijuana producer in Canada, Aurora Cannabis (NYSE: ACB), has made clear that its focus will be on the medical marijuana community. When asked about the state of the cannabis oil and flower market, Jordan had this to say: What's very interesting is that if you were to look at the cannabis mark... | For example, the largest marijuana producer in Canada, Aurora Cannabis (NYSE: ACB), has made clear that its focus will be on the medical marijuana community. When asked about the state of the cannabis oil and flower market, Jordan had this to say: What's very interesting is that if you were to look at the cannabis mark... |
38463.0 | 2019-05-03 00:00:00 UTC | 3 of the Biggest Pot Stocks Have a Lot to Prove | ACB | https://www.nasdaq.com/articles/3-biggest-pot-stocks-have-lot-prove-2019-05-03 | nan | nan | In case you haven't noticed, marijuana stocks are going bonkers, once again. After logging an abysmal fourth quarter, pot stocks have been blazing hot since 2019 began. Through Monday's close (April 29), the first-ever cannabis exchange-traded fund, the Horizons Marijuana Life Sciences ETF, had tripled the return of th... | Aurora Cannabis The second-largest marijuana stock in the world by market cap, Aurora Cannabis (NYSE: ACB), also needs to do quite a bit to live up to the ridiculous amount of hype currently surrounding it. Through Monday's close (April 29), the first-ever cannabis exchange-traded fund, the Horizons Marijuana Life Scie... | Aurora Cannabis The second-largest marijuana stock in the world by market cap, Aurora Cannabis (NYSE: ACB), also needs to do quite a bit to live up to the ridiculous amount of hype currently surrounding it. At this point, even with recurring positive EBITDA (earnings before interest, taxes, depreciation, and amortizati... | Aurora Cannabis The second-largest marijuana stock in the world by market cap, Aurora Cannabis (NYSE: ACB), also needs to do quite a bit to live up to the ridiculous amount of hype currently surrounding it. Cronos Group Perhaps no company causes me to scratch my head in disbelief more than Cronos Group (NASDAQ: CRON), ... | Aurora Cannabis The second-largest marijuana stock in the world by market cap, Aurora Cannabis (NYSE: ACB), also needs to do quite a bit to live up to the ridiculous amount of hype currently surrounding it. With a market cap of close to $5.3 billion, GW Pharmaceuticals is being priced as if Epidiolex will grow into a $... |
38464.0 | 2019-05-02 00:00:00 UTC | Wait for Earnings Before Trading Aurora Cannabis Stock | ACB | https://www.nasdaq.com/articles/wait-earnings-trading-aurora-cannabis-stock-2019-05-02 | nan | nan | Aurora Cannabis (NYSE:) stock has plateaued over the last few weeks. Since again surpassing the $10 per share range in March, ACB stock has retreated. Shares of the marijuana stock have traded just above the $9 per share range as the equity awaits a catalyst.
Source: Shutterstock
Aurora’s production levels ensure that ... | ACB Stock Passes the “Smell Test” in Many Respects My InvestorPlace colleague Will Ashworth points to the emanating from the Aurora facility near the airport in Edmonton, Alberta as a bullish sign. Until ACB breaches the double top or pulls back significantly, traders have few obvious reasons to buy in the near term. S... | Since again surpassing the $10 per share range in March, ACB stock has retreated. A considerable pullback or attracting a large investor could also make ACB stock a buy. However, I see little near-term upside for ACB without such a meaningful catalyst. | ACB Stock Needs a Catalyst to Become a Buy Still, this does not make Aurora Cannabis stock a buy at these levels. The Bottom Line on ACB Stock ACB stock will need a catalyst of some kind to move higher. Since again surpassing the $10 per share range in March, ACB stock has retreated. | ACB Stock Needs a Catalyst to Become a Buy Still, this does not make Aurora Cannabis stock a buy at these levels. If a positive report takes ACB sustainably above $10 per share, it could move higher. Since again surpassing the $10 per share range in March, ACB stock has retreated. |
38465.0 | 2019-05-01 00:00:00 UTC | Marijuana: A $166 Billion Market? | ACB | https://www.nasdaq.com/articles/marijuana%3A-166-billion-market-2019-05-01 | nan | nan | Marijuana may be "just a plant," but it has Wall Street and investors seeing green and grinning ear to ear at its long-term growth potential.
Long considered a taboo topic, cannabis has forced its way into the mainstream. In the United States, where favorability toward broad-based legalization stood at just 25% in 1995... | While not top picks, Carey also believes investors can't go wrong with Aurora Cannabis (NYSE: ACB) or Canopy Growth (NYSE: CGC), which were also bestowed with a buy rating. This includes addressing the massive black market by legalizing cannabis in the United States and other developed countries, and in the interim con... | While not top picks, Carey also believes investors can't go wrong with Aurora Cannabis (NYSE: ACB) or Canopy Growth (NYSE: CGC), which were also bestowed with a buy rating. Meanwhile, the largest marijuana stock in the world by market cap, Canopy Growth, has a massive balance sheet, with $3.7 billion in cash and cash e... | While not top picks, Carey also believes investors can't go wrong with Aurora Cannabis (NYSE: ACB) or Canopy Growth (NYSE: CGC), which were also bestowed with a buy rating. The global weed industry could be bigger than you realize For those who may not recall, Owen Bennett, the covering analyst at Jefferies, forecast $... | While not top picks, Carey also believes investors can't go wrong with Aurora Cannabis (NYSE: ACB) or Canopy Growth (NYSE: CGC), which were also bestowed with a buy rating. Aurora Cannabis is easy for most Wall Street firms to like because of its industry-leading production potential and superior global presence. Crono... |
38466.0 | 2019-05-01 00:00:00 UTC | Could Organigram's Q2 Results Hint at What's to Come for Aurora Cannabis and Canopy Growth? | ACB | https://www.nasdaq.com/articles/could-organigrams-q2-results-hint-whats-come-aurora-cannabis-and-canopy-growth-2019-05-01 | nan | nan | We have to wait a few weeks for the two biggest Canadian marijuana producers to report their first results that will include adult-use recreational marijuana sales in 2019. Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) haven't even scheduled their quarterly updates yet.
However, Organigram Holdings (NASDAQO... | Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) haven't even scheduled their quarterly updates yet. Also, Organigram's large number of SKUs (stock-keeping units) might have played a role in its success in Ontario, Canada's largest province. With international medical cannabis markets expanding, particularly i... | Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) haven't even scheduled their quarterly updates yet. We have to wait a few weeks for the two biggest Canadian marijuana producers to report their first results that will include adult-use recreational marijuana sales in 2019. Aurora Cannabis and Canopy Growth wil... | Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) haven't even scheduled their quarterly updates yet. You might think that Organigram's Q2 results don't mean much in trying to get a feel for how well Aurora and Canopy might perform in the next quarterly updates. But there's at least one important takeaway from ... | Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) haven't even scheduled their quarterly updates yet. We have to wait a few weeks for the two biggest Canadian marijuana producers to report their first results that will include adult-use recreational marijuana sales in 2019. Aurora Cannabis and Canopy Growth wil... |
38467.0 | 2019-04-30 00:00:00 UTC | These Top Marijuana Stocks Have the Best Profit Margin | ACB | https://www.nasdaq.com/articles/these-top-marijuana-stocks-have-best-profit-margin-2019-05-01 | nan | nan | Shifting marijuana sales out of the shadows to legal marijuana dispensaries is a multibillion-dollar opportunity, so cannabis companies are spending big money to win market share early on. The flurry of spending means the marijuana industry is losing money right now, but some companies offer better gross margin than ot... | Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) are in the top tier with over $200 million Canadian dollars in annualized sales and production forecasts exceeding 500,000 kilos per year. The flurry of spending means the marijuana industry is losing money right now, but some companies offer better gross margin... | Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) are in the top tier with over $200 million Canadian dollars in annualized sales and production forecasts exceeding 500,000 kilos per year. The flurry of spending means the marijuana industry is losing money right now, but some companies offer better gross margin... | Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) are in the top tier with over $200 million Canadian dollars in annualized sales and production forecasts exceeding 500,000 kilos per year. As such, gross margin helps investors determine what company is producing marijuana at the lowest cost, or is selling the m... | Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) are in the top tier with over $200 million Canadian dollars in annualized sales and production forecasts exceeding 500,000 kilos per year. Who has the best gross margin? Excluding those fair-value changes, OrganiGram's gross margin of 60% during its most recent ... |
38468.0 | 2019-04-30 00:00:00 UTC | 3 Pot Stocks Selling the Most Recreational Marijuana | ACB | https://www.nasdaq.com/articles/3-pot-stocks-selling-most-recreational-marijuana-2019-04-30 | nan | nan | In case you haven't noticed, big things are happening with the legal marijuana industry. It's already growing at an impressive pace, and excitement surrounding the legal pot industry really took off following the legalization of recreational marijuana in Canada in October. Eventually, Wall Street is looking for the can... | OrganiGram Holdings: CA$30.7 million in gross recreational sales Perhaps the biggest surprise is that Aurora Cannabis (NYSE: ACB), which projects to be the leading producer throughout all of Canada, isn't in the No. Few pot stocks leaned more convincingly to the recreational side of the market during the first quarter ... | OrganiGram Holdings: CA$30.7 million in gross recreational sales Perhaps the biggest surprise is that Aurora Cannabis (NYSE: ACB), which projects to be the leading producer throughout all of Canada, isn't in the No. With close to 490,000 square feet of aggregate production space at its Moncton campus, OrganiGram expect... | OrganiGram Holdings: CA$30.7 million in gross recreational sales Perhaps the biggest surprise is that Aurora Cannabis (NYSE: ACB), which projects to be the leading producer throughout all of Canada, isn't in the No. Canopy Growth: 71.6 million Canadian dollars in gross recreational sales In mid-February, the largest ca... | OrganiGram Holdings: CA$30.7 million in gross recreational sales Perhaps the biggest surprise is that Aurora Cannabis (NYSE: ACB), which projects to be the leading producer throughout all of Canada, isn't in the No. Aurora Cannabis: CA$26.5 million in gross recreational sales The third leading marijuana stock generatin... |
38469.0 | 2019-04-30 00:00:00 UTC | Why Millennial Investors Are Buying Aurora Cannabis and Cronos Group Above All Other Pot Stocks | ACB | https://www.nasdaq.com/articles/why-millennial-investors-are-buying-aurora-cannabis-and-cronos-group-above-all-other-pot | nan | nan | It's no secret that younger Americans are more supportive of marijuana legalization. It appears that they're pretty upbeat on marijuana stocks, too.
The free investing app Robinhood is especially popular with millennial investors, which consist of individuals born between 1981 and 1996. Of the five most widely held st... | Of the five most widely held stocks on Robinhood, two of them are pot stocks -- Aurora Cannabis (NYSE: ACB) and Cronos Group (NASDAQ: CRON). A handful of stocks with significant financial interests in the cannabis industry are also listed on the NYSE, including Altria, Constellation Brands, and Scotts Miracle-Gro. Sinc... | Of the five most widely held stocks on Robinhood, two of them are pot stocks -- Aurora Cannabis (NYSE: ACB) and Cronos Group (NASDAQ: CRON). Currently, there are only six pure-play pot stocks that trade on the New York Stock Exchange (NYSE): Aurora Cannabis, Aphria, Canopy Growth, CannTrust Holdings, Innovative Industr... | Of the five most widely held stocks on Robinhood, two of them are pot stocks -- Aurora Cannabis (NYSE: ACB) and Cronos Group (NASDAQ: CRON). Currently, there are only six pure-play pot stocks that trade on the New York Stock Exchange (NYSE): Aurora Cannabis, Aphria, Canopy Growth, CannTrust Holdings, Innovative Industr... | Of the five most widely held stocks on Robinhood, two of them are pot stocks -- Aurora Cannabis (NYSE: ACB) and Cronos Group (NASDAQ: CRON). Positive publicity Millennials are more likely to buy the products that they know about. And they're more likely to invest in the marijuana stocks that they know about. |
38470.0 | 2019-04-29 00:00:00 UTC | Meet Marijuana's 14 Billion-Dollar Pot Stocks | ACB | https://www.nasdaq.com/articles/meet-marijuanas-14-billion-dollar-pot-stocks-2019-04-29 | nan | nan | Few if any industries have been as impressive over the past couple of years as the legal cannabis industry. With Canada becoming the first industrialized country in the world to wave the green flag on adult-use pot, and more than 40 countries giving the OK to medical cannabis in some capacity, Wall Street and investors... | Aurora Cannabis: $9.22 billion Aurora Cannabis (NYSE: ACB) is arguably the most popular pot stock among millennials. Assuming all existing deals close, Harvest Health will have 213 total licenses, including the right to open 130 retail locations, which is tops among publicly traded dispensary operators. It also somewha... | Aurora Cannabis: $9.22 billion Aurora Cannabis (NYSE: ACB) is arguably the most popular pot stock among millennials. Canopy has more cash and cash equivalents at its disposal (thanks to a huge $4 billion equity investment from Constellation Brands) than any other pot stock, and is projected to be Canada's second-larges... | Aurora Cannabis: $9.22 billion Aurora Cannabis (NYSE: ACB) is arguably the most popular pot stock among millennials. Canopy has more cash and cash equivalents at its disposal (thanks to a huge $4 billion equity investment from Constellation Brands) than any other pot stock, and is projected to be Canada's second-larges... | Aurora Cannabis: $9.22 billion Aurora Cannabis (NYSE: ACB) is arguably the most popular pot stock among millennials. It also somewhat recently announced the acquisition of Newstrike Brands for $197 million, which will be responsible for boosting its peak annual output from 108,000 to 150,000 kilos, making HEXO a top-si... |
38471.0 | 2019-04-29 00:00:00 UTC | This Crazy Accounting Rule Could Be Very Dangerous for Marijuana Investors | ACB | https://www.nasdaq.com/articles/crazy-accounting-rule-could-be-very-dangerous-marijuana-investors-2019-04-29 | nan | nan | Accounting rules are supposed to give investors uniform rules of the road by which to analyze companies. Sometimes, however, rules that attempt to "fix" industries with quirky or lumpy revenues introduce undue complications, missing the original goal and actually making things more convoluted. An example of this happen... | Sometimes, however, rules that attempt to "fix" industries with quirky or lumpy revenues introduce undue complications, missing the original goal and actually making things more convoluted. As the cannabis plant grows and flowers, companies must record the profit it could fetch at that particular moment, based on the c... | New rules state that Berkshire must record unrealized capital gains on its stock holdings as earnings, meaning Berkshire's earnings will fluctuate wildly with the market's moves each quarter, as it's essentially a holding company of other publicly-traded companies. If these busts continue to happen in the cannabis indu... | New rules state that Berkshire must record unrealized capital gains on its stock holdings as earnings, meaning Berkshire's earnings will fluctuate wildly with the market's moves each quarter, as it's essentially a holding company of other publicly-traded companies. As the cannabis plant grows and flowers, companies mus... | Another example has unfortunately happened to the cannabis industry. In fact, a "bust" happened at the end of last year, when the price of wholesale cannabis declined between 3% and 53%, depending on which U.S. state you were in. If these busts continue to happen in the cannabis industry, there could future periods whe... |
38472.0 | 2019-04-28 00:00:00 UTC | 3 High-Flying Pot Stocks to Buy | ACB | https://www.nasdaq.com/articles/3-high-flying-pot-stocks-buy-2019-04-28 | nan | nan | If you're considering pot stocks for your portfolio, you could be on to something. The marijuana market is worth $150 billion per year worldwide, and the potential to create new cannabis-derived products, including beverages and edibles, has beer and wine giant Constellation Brands (NYSE: STZ) thinking legal marijuana ... | It's too early to know for sure which companies will be the biggest winners, but HEXO (NYSEMKT: HEXO), CannTrust Holdings (NYSE: CTST), and Aurora Cannabis (NYSE: ACB) may be the best marijuana stocks to buy right now to take advantage of this upcoming windfall. The company only recently jumped toward the front of the ... | It's too early to know for sure which companies will be the biggest winners, but HEXO (NYSEMKT: HEXO), CannTrust Holdings (NYSE: CTST), and Aurora Cannabis (NYSE: ACB) may be the best marijuana stocks to buy right now to take advantage of this upcoming windfall. Previously, it was targeting peak pot production of 108,0... | It's too early to know for sure which companies will be the biggest winners, but HEXO (NYSEMKT: HEXO), CannTrust Holdings (NYSE: CTST), and Aurora Cannabis (NYSE: ACB) may be the best marijuana stocks to buy right now to take advantage of this upcoming windfall. Since its production forecast is double that of HEXO and ... | It's too early to know for sure which companies will be the biggest winners, but HEXO (NYSEMKT: HEXO), CannTrust Holdings (NYSE: CTST), and Aurora Cannabis (NYSE: ACB) may be the best marijuana stocks to buy right now to take advantage of this upcoming windfall. Since its production forecast is double that of HEXO and ... |
38473.0 | 2019-04-28 00:00:00 UTC | Mexico Aims to Legalize Recreational Marijuana Before October | ACB | https://www.nasdaq.com/articles/mexico-aims-legalize-recreational-marijuana-october-2019-04-28 | nan | nan | Momentum within the marijuana industry is undeniable. Since 1995, we've seen support for broad-based legalization in the U.S. catapult from just 25% to 66% in October 2018, according to Gallup's national poll. We've also gone from having zero U.S. states legalized for medical or recreational purposes in 1995 to 33 stat... | But should full legalization occur within the next few months, Aurora Cannabis (NYSE: ACB) and, to a lesser extent Canopy Growth (NYSE: CGC), should be sitting pretty. Should Mexico indeed move forward with legalization before October, as well as develop a plan to reduce or eliminate cartel interference, it could be on... | But should full legalization occur within the next few months, Aurora Cannabis (NYSE: ACB) and, to a lesser extent Canopy Growth (NYSE: CGC), should be sitting pretty. We've also gone from having zero U.S. states legalized for medical or recreational purposes in 1995 to 33 states having approved medical marijuana as of... | But should full legalization occur within the next few months, Aurora Cannabis (NYSE: ACB) and, to a lesser extent Canopy Growth (NYSE: CGC), should be sitting pretty. Mexico plans to roll out the green carpet before October In June 2017, Mexico became one of the aforementioned 40-plus countries to legalize medical mar... | But should full legalization occur within the next few months, Aurora Cannabis (NYSE: ACB) and, to a lesser extent Canopy Growth (NYSE: CGC), should be sitting pretty. With this medical pot infrastructure already in place, the time has come for Mexico take the next logical step and become the third country worldwide to... |
38474.0 | 2019-04-28 00:00:00 UTC | Marijuana Stocks: Breaking Down the Recreational-to-Medical Sales Ratio of the Top Growers | ACB | https://www.nasdaq.com/articles/marijuana-stocks-breaking-down-recreational-medical-sales-ratio-top-growers-2019-04-28 | nan | nan | Interest in the marijuana industry is heating up among investors, and for good reason. Since the year began, the very first tradable cannabis exchange-traded fund, the Horizons Marijuana Life Sciences ETF, has practically tripled the returns of the broad-based S&P 500, which is having a stellar year of its own.
The leg... | Aurora Cannabis: 45.4% recreational, 54.6% medical One of the more eye-popping statistics in the most recent round of quarterly reports for the marijuana industry was that of Aurora Cannabis (NYSE: ACB). This sales breakdown probably also provides a pretty good clue as to why Canopy Growth has earned the right to acqui... | Aurora Cannabis: 45.4% recreational, 54.6% medical One of the more eye-popping statistics in the most recent round of quarterly reports for the marijuana industry was that of Aurora Cannabis (NYSE: ACB). Let's take a closer look at the recreational-to-medical sales ratio breakdown of five of Canada's largest pot grower... | Aurora Cannabis: 45.4% recreational, 54.6% medical One of the more eye-popping statistics in the most recent round of quarterly reports for the marijuana industry was that of Aurora Cannabis (NYSE: ACB). According to the fourth-quarter National Cannabis Survey in Canada, medical pot patients use the product more freque... | Aurora Cannabis: 45.4% recreational, 54.6% medical One of the more eye-popping statistics in the most recent round of quarterly reports for the marijuana industry was that of Aurora Cannabis (NYSE: ACB). HEXO: 91.2% recreational, 8.8% medical Next to Aurora Cannabis selling more medical marijuana than adult-use pot, pe... |
38475.0 | 2019-04-28 00:00:00 UTC | 3 Reasons Aurora Cannabis Is a Better Pot Stock Than Canopy Growth, and 1 Big Reason It Isn't | ACB | https://www.nasdaq.com/articles/3-reasons-aurora-cannabis-better-pot-stock-canopy-growth-and-1-big-reason-it-isnt-2019-04 | nan | nan | No. 2. Runner-up. Second fiddle. All these terms have applied to Aurora Cannabis (NYSE: ACB) over the past couple of years. Even as the Canadian marijuana producer made one acquisition after another to fuel growth, it seemed to still always trail behind one other company. That company, of course, is Canopy Growth (NYSE... | All these terms have applied to Aurora Cannabis (NYSE: ACB) over the past couple of years. Cowen analyst Vivien Azer replaced Canopy Growth with Aurora as her top pick among marijuana stocks. Lower valuation Aurora isn't close to dethroning Canopy Growth when it comes to which company has the highest market cap. | All these terms have applied to Aurora Cannabis (NYSE: ACB) over the past couple of years. Greater production capacity Vivien Azer's top reason for making Aurora her top marijuana stock pick is the company's production capacity. But here's why Canopy Growth is still better With a lower valuation, greater production cap... | All these terms have applied to Aurora Cannabis (NYSE: ACB) over the past couple of years. There's a strong argument to be made that Aurora Cannabis is now a better pot stock than Canopy Growth. Lower valuation Aurora isn't close to dethroning Canopy Growth when it comes to which company has the highest market cap. | All these terms have applied to Aurora Cannabis (NYSE: ACB) over the past couple of years. Aurora was one of the three; Canopy Growth wasn't. But here's why Canopy Growth is still better With a lower valuation, greater production capacity, and stronger international presence, you might think that Aurora would be a shoo... |
38476.0 | 2019-04-28 00:00:00 UTC | Better Buy: Aurora Cannabis vs. Scotts Miracle-Gro | ACB | https://www.nasdaq.com/articles/better-buy-aurora-cannabis-vs-scotts-miracle-gro-2019-04-28 | nan | nan | Looking for winning marijuana stocks? Two that probably should be on your short list are Aurora Cannabis (NYSE: ACB) and Scotts Miracle-Gro (NYSE: SMG). Shares of Aurora have soared more than 80% so far this year, while Scotts Miracle-Gro stock is up more than 35%.
If you can afford to invest in only one marijuana stoc... | Two that probably should be on your short list are Aurora Cannabis (NYSE: ACB) and Scotts Miracle-Gro (NYSE: SMG). Based on results from the first full quarter to include adult-use recreational sales, Aurora is in second place in the important market. Aurora tapped billionaire investor Nelson Peltz as a strategic advis... | Two that probably should be on your short list are Aurora Cannabis (NYSE: ACB) and Scotts Miracle-Gro (NYSE: SMG). The case for Aurora Cannabis Aurora Cannabis' revenue continues to soar thanks to the Canadian adult-use recreational marijuana market. The company thinks that there could be up to a $9 billion annual mark... | Two that probably should be on your short list are Aurora Cannabis (NYSE: ACB) and Scotts Miracle-Gro (NYSE: SMG). The case for Aurora Cannabis Aurora Cannabis' revenue continues to soar thanks to the Canadian adult-use recreational marijuana market. The case for Scotts Miracle-Gro Scotts Miracle-Gro has been best know... | Two that probably should be on your short list are Aurora Cannabis (NYSE: ACB) and Scotts Miracle-Gro (NYSE: SMG). The biggest of these states, California, launched its adult-use recreational marijuana market last year. What's the second growth opportunity for Hawthorne? |
38477.0 | 2019-04-27 00:00:00 UTC | Uh-Oh! Canadian Marijuana Sales Have Declined 2 Straight Months | ACB | https://www.nasdaq.com/articles/uh-oh-canadian-marijuana-sales-have-declined-2-straight-months-2019-04-27 | nan | nan | The legalization of marijuana is expected to lead to one of the strongest long-term growth trends we've seen in a generation. Having registered global sales of $12.2 billion in 2018, the cannabis industry is expected to grow revenue 38% in 2019, to $16.9 billion, and practically double worldwide sales again by 2022, to... | Although it could be hurt to a lesser extent than Canopy Growth, due to its greater reliance on the medical cannabis community, Aurora Cannabis (NYSE: ACB) could see its organic sales growth slow dramatically in the upcoming fiscal third quarter. Health Canada laid out a gauntlet of guidelines that must be adhered to i... | Although it could be hurt to a lesser extent than Canopy Growth, due to its greater reliance on the medical cannabis community, Aurora Cannabis (NYSE: ACB) could see its organic sales growth slow dramatically in the upcoming fiscal third quarter. Depending on your preferred source, Wall Street believes that the global ... | Although it could be hurt to a lesser extent than Canopy Growth, due to its greater reliance on the medical cannabis community, Aurora Cannabis (NYSE: ACB) could see its organic sales growth slow dramatically in the upcoming fiscal third quarter. Having registered global sales of $12.2 billion in 2018, the cannabis ind... | Although it could be hurt to a lesser extent than Canopy Growth, due to its greater reliance on the medical cannabis community, Aurora Cannabis (NYSE: ACB) could see its organic sales growth slow dramatically in the upcoming fiscal third quarter. As a whole, legal pot sales in February were 13% lower than in December, ... |
38478.0 | 2019-04-27 00:00:00 UTC | Why Aurora Cannabis' Latest Technology Deal Matters More Than You Might Think | ACB | https://www.nasdaq.com/articles/why-aurora-cannabis-latest-technology-deal-matters-more-you-might-think-2019-04-27 | nan | nan | For Aurora Cannabis (NYSE: ACB), 10 million Canadian dollars (roughly $7.4 million) is pretty much chump change. Sure, it's nearly one-fifth of the Canadian marijuana producer's sales last quarter. But in the grand scheme of things, it isn't a lot for Aurora to spend.
So when Aurora announced on Friday that it was inve... | For Aurora Cannabis (NYSE: ACB), 10 million Canadian dollars (roughly $7.4 million) is pretty much chump change. So when Aurora announced on Friday that it was investing that amount in Vancouver-based technology company EnWave (NASDAQOTH: NWVCF), the news wasn't met with major fanfare. As Aurora Cannabis CEO Terry Boot... | For Aurora Cannabis (NYSE: ACB), 10 million Canadian dollars (roughly $7.4 million) is pretty much chump change. The two companies also entered into an agreement that gives Aurora exclusive rights to use EnWave's Radiant Energy Vacuum (REV) drying technology in all European Union countries in except Portugal, plus a no... | For Aurora Cannabis (NYSE: ACB), 10 million Canadian dollars (roughly $7.4 million) is pretty much chump change. The two companies also entered into an agreement that gives Aurora exclusive rights to use EnWave's Radiant Energy Vacuum (REV) drying technology in all European Union countries in except Portugal, plus a no... | For Aurora Cannabis (NYSE: ACB), 10 million Canadian dollars (roughly $7.4 million) is pretty much chump change. But this deal might be more important over the long run for Aurora than you'd expect. However, it's another example of how the company is differentiating itself from other major marijuana producers. |
38479.0 | 2019-04-26 00:00:00 UTC | Meet the Aurora Cannabis of U.S. Dispensary Stocks | ACB | https://www.nasdaq.com/articles/meet-aurora-cannabis-us-dispensary-stocks-2019-04-26 | nan | nan | The marijuana industry is evolving at an incredible pace. As recently as the midpoint of the past decade, no countries had given recreational weed the green light, and only a select few U.S. states had medical cannabis laws on their books. Today, two-thirds of all U.S. states have passed medical marijuana laws; 66% of ... | And when it comes to production, that company is Aurora Cannabis (NYSE: ACB). As recently as the midpoint of the past decade, no countries had given recreational weed the green light, and only a select few U.S. states had medical cannabis laws on their books. Over just the past six months, Harvest Health has completed ... | And when it comes to production, that company is Aurora Cannabis (NYSE: ACB). Though some of its largest projects are organic builds, including the Aurora Sun project (1.62 million square feet) and the Aurora Sky campus (800,000 square feet), it paid about $2 billion to buy MedReleaf, $850 million for CanniMed Therapeu... | And when it comes to production, that company is Aurora Cannabis (NYSE: ACB). Say hello to the U.S. version of Aurora Cannabis Cannabis companies want to emulate Aurora's growth strategy, and one U.S.-focused vertically integrated dispensary stock -- i.e., a dispensary operator that controls its cannabis supply chain -... | And when it comes to production, that company is Aurora Cannabis (NYSE: ACB). Aurora and Harvest Health share many similarities How exactly is this like Aurora? While Harvest Health currently operates 10 cannabis stores in four states, it will have licenses to operate 213 facilities in 17 states if its Falcon, Verano, ... |
38480.0 | 2019-04-26 00:00:00 UTC | 2 Under-The-Radar Cannabis Stocks with Significant Growth Potential | ACB | https://www.nasdaq.com/articles/2-under-radar-cannabis-stocks-significant-growth-potential-2019-04-26 | nan | nan | Hexo (NYSE: ) and Supreme Cannabis (OTC: ) are two options that still have significant upside for investors, which isn’t easy to say for many cannabis stocks.
Source: Shutterstock
It’s been a good year for cannabis stocks. But with several of the largest, most popular cannabis stocks already up more than 70% year-to-d... | Hexo recently announced a buyout of Canada’s Newstrike Brands for $263 million, the largest merger between two Canadian cannabis producers in history. However, for investors looking for a long-term play on the cannabis trend, Hexo’s $1.4 billion market cap leaves plenty of room for expansion. “It is compelling on valua... | Cannabis Stocks To Buy: HEXO Surprisingly, Bank of America analyst Christopher Carey named HEXO stock his top cannabis pick. Canopy’s $16.2 billion market cap and Aurora’s $9.1 billion market cap reflect those positions. Cannabis Stocks To Buy: Supreme Cannabis Hexo caught many stock investors off guard as Bank of Amer... | Hexo (NYSE: ) and Supreme Cannabis (OTC: ) are two options that still have significant upside for investors, which isn’t easy to say for many cannabis stocks. Cannabis Stocks To Buy: HEXO Surprisingly, Bank of America analyst Christopher Carey named HEXO stock his top cannabis pick. Cannabis Stocks To Buy: Supreme Cann... | Cannabis Stocks To Buy: HEXO Surprisingly, Bank of America analyst Christopher Carey named HEXO stock his top cannabis pick. Hexo is a cannabis company based in Quebec that has national distribution in Canada. As of 2019, the company operates mostly in the Canadian market. |
38481.0 | 2019-04-26 00:00:00 UTC | Odor Complaints Make a Great Case for Buying ACB Stock | ACB | https://www.nasdaq.com/articles/odor-complaints-make-great-case-buying-acb-stock-2019-04-26 | nan | nan | Aurora Cannabis (NYSE:) has an odor issue, and it’s got nothing to do with ACB stock. It turns out that Aurora’s 800,000 square-foot Aurora Sky grow op in Edmonton, Alberta is adjacent to the city’s international airport.
Source: Shutterstock
In December, in response to complaints from people working near and at the ai... | Those of us who write about ACB stock and all the other cannabis companies operating in Canada, the U.S., and the rest of the world, tend to throw out figures like candy. Not even , the first Wall Street analyst to cover cannabis could move me off my perch with positive comments about Aurora: “ACB is well positioned to... | Aurora Cannabis (NYSE:) has an odor issue, and it’s got nothing to do with ACB stock. “In fact, it’s the terpenes, the aromatic compound that gives each strain of cannabis its particular smell and taste.” If you’re an ACB shareholder, you’ve got to consider this situation to be a win for the company. Those of us who wr... | Not even , the first Wall Street analyst to cover cannabis could move me off my perch with positive comments about Aurora: “ACB is well positioned to benefit in the early innings of the Canadian adult use market, given its impressive 20% market share to date and #2 position by in-stock (stock keeping units), based on o... | Aurora Cannabis (NYSE:) has an odor issue, and it’s got nothing to do with ACB stock. “In fact, it’s the terpenes, the aromatic compound that gives each strain of cannabis its particular smell and taste.” If you’re an ACB shareholder, you’ve got to consider this situation to be a win for the company. Those of us who wr... |
38482.0 | 2019-04-25 00:00:00 UTC | This Is the Craziest Marijuana Statistic You'll See | ACB | https://www.nasdaq.com/articles/craziest-marijuana-statistic-youll-see-2019-04-25 | nan | nan | The world is "going green" at an incredibly fast pace, and investors have taken notice. The rise of the legal cannabis industry has been undeniable, with global sales growing to $12.2 billion in 2018, and worldwide revenue forecast to rise to more than $31 billion by 2022. Ultimately, we could be looking at an industry... | Aurora Cannabis (NYSE: ACB) could be producing as much as 780,000 kilos a year by 2022 but currently has a run rate of a little more than 150,000 kilos. Canopy Growth (NYSE: CGC) wasn't spared, either, with GMP Securities moving the largest pot stock in the world by market cap from a buy to hold on February 19. Tax rev... | Aurora Cannabis (NYSE: ACB) could be producing as much as 780,000 kilos a year by 2022 but currently has a run rate of a little more than 150,000 kilos. Cronos Group (NASDAQ: CRON) has been downgraded on three separate occasions since Feb. 5, 2019, with GMP Securities, BMO Capital, and Canaccord Genuity moving Cronos t... | Aurora Cannabis (NYSE: ACB) could be producing as much as 780,000 kilos a year by 2022 but currently has a run rate of a little more than 150,000 kilos. Since roughly the midpoint of last year, quite a few pot stocks have had coverage initiated by Wall Street, with an assortment of buy, hold, and sell ratings to go aro... | Aurora Cannabis (NYSE: ACB) could be producing as much as 780,000 kilos a year by 2022 but currently has a run rate of a little more than 150,000 kilos. There have been how many marijuana stock upgrades? Since roughly the midpoint of last year, quite a few pot stocks have had coverage initiated by Wall Street, with an ... |
38483.0 | 2019-04-24 00:00:00 UTC | A Game-Changing Moment for Marijuana Stocks Just Got Closer | ACB | https://www.nasdaq.com/articles/game-changing-moment-marijuana-stocks-just-got-closer-2019-04-24 | nan | nan | Last week, a blockbuster story for marijuana stocks — one of the biggest in years — slipped by a lot of investors. It was in the news, but most investors don’t know the industry well enough or the players involved to grasp its huge significance. To them, it was just another headline.
Not to me. I’ve been waiting years... | But I believe it to be true because of three very important people on the board of Acreage Holdings: Former Canadian Prime Minister Brian Mulroney, Among those three gentlemen, there is undoubtedly insight into marijuana’s future that you and I are not yet privy to. Now is the Time Instead of buying Acreage outright to... | In fact, any company that touches the marijuana plant in the United States cannot list on a major stock exchange — the New York Stock Exchange (NYSE), NASDAQ, even the Toronto Stock Exchange (TSX). Now is the Time Instead of buying Acreage outright today, Canopy wisely bought the “rights” to purchase the company when m... | Basically, the biggest marijuana company in the world and some of the most connected people in the world all but told us that U.S. marijuana legalization is coming… and perhaps sooner than expected. In fact, any company that touches the marijuana plant in the United States cannot list on a major stock exchange — the Ne... | Basically, the biggest marijuana company in the world and some of the most connected people in the world all but told us that U.S. marijuana legalization is coming… and perhaps sooner than expected. And Canopy wouldn’t do that if legalization were still years away. Canopy Growth is not just any marijuana company. |
38484.0 | 2019-04-24 00:00:00 UTC | Shelf Offerings Could Cripple These 2 Pot Stocks in the Near Term | ACB | https://www.nasdaq.com/articles/shelf-offerings-could-cripple-these-2-pot-stocks-near-term-2019-04-24 | nan | nan | There's arguably no hotter than industry right now than legal marijuana, and the data proves it. Since the year began, the Horizons Marijuana Life Sciences ETF, the first-ever cannabis exchange-traded fund, which now holds about four dozen pot stocks of various weightings, has nearly tripled the performance of the broa... | Aurora Cannabis Among marijuana growers, there's no company right now that's on track for more output per year at its peak than Aurora Cannabis (NYSE: ACB). Since the year began, the Horizons Marijuana Life Sciences ETF, the first-ever cannabis exchange-traded fund, which now holds about four dozen pot stocks of variou... | Aurora Cannabis Among marijuana growers, there's no company right now that's on track for more output per year at its peak than Aurora Cannabis (NYSE: ACB). For instance, Modelo and Corona beer maker Constellation Brands (NYSE: STZ) made three separate investments in Canopy Growth (NYSE: CGC), including a $4 billion eq... | Aurora Cannabis Among marijuana growers, there's no company right now that's on track for more output per year at its peak than Aurora Cannabis (NYSE: ACB). Shelf offerings could pester the shareholders of these two pot stocks But most pot stocks aren't lucky enough to have an ample supply of cash at the ready to deplo... | Aurora Cannabis Among marijuana growers, there's no company right now that's on track for more output per year at its peak than Aurora Cannabis (NYSE: ACB). As for Canopy Growth, it walks away with a lot of cash ($3.7 billion in cash and cash equivalents as of the end of 2018) that it can use to make acquisitions. 10 s... |
38485.0 | 2019-04-24 00:00:00 UTC | A Top Wall Street Analyst Loves Aurora Cannabis, Canopy Growth, and HEXO -- Should You? | ACB | https://www.nasdaq.com/articles/top-wall-street-analyst-loves-aurora-cannabis-canopy-growth-and-hexo-should-you-2019-04-24 | nan | nan | Once upon a time, Wall Street analysts wouldn't touch a marijuana stock with a 10-foot pole. Now many of the same analysts are cuddling up to quite a few pot stocks.
The latest example of Wall Street's fascination comes from Bank of America. Last week, analyst Christopher Carey initiated coverage on three marijuana sto... | Last week, analyst Christopher Carey initiated coverage on three marijuana stocks with positive views: Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and HEXO (NYSEMKT: HEXO). Aurora recently brought billionaire Nelson Peltz on board as a strategic advisor to use his extensive connections to help find partners... | Last week, analyst Christopher Carey initiated coverage on three marijuana stocks with positive views: Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and HEXO (NYSEMKT: HEXO). But while this top Wall Street analyst loves these three pot stocks, should you? One is the growth opportunity in the Canadian adult-us... | Last week, analyst Christopher Carey initiated coverage on three marijuana stocks with positive views: Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and HEXO (NYSEMKT: HEXO). HEXO isn't nearly as big as Aurora Cannabis or Canopy Growth. Aurora Cannabis and Canopy Growth are likely to be top contenders as the ... | Last week, analyst Christopher Carey initiated coverage on three marijuana stocks with positive views: Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and HEXO (NYSEMKT: HEXO). HEXO isn't nearly as big as Aurora Cannabis or Canopy Growth. But Bank of America's Carey thinks that it's possible that HEXO could dev... |
38486.0 | 2019-04-23 00:00:00 UTC | The Most Hated Pot Stock Logs Another Sell Rating | ACB | https://www.nasdaq.com/articles/most-hated-pot-stock-logs-another-sell-rating-2019-04-23 | nan | nan | The marijuana industry is transforming before our eyes, and Wall Street is taking notice. Over the past couple of months, quite a few Wall Street investment banks have chimed in on the long-term sales outlook for the industry, as well as initiated coverage on a handful of marijuana stocks.
For example, the cannabis ind... | For example, the cannabis industry's biggest cheerleader, Cowen Group, is looking for $75 billion in global sales by 2030, up from $12.2 billion in 2018, and has named Aurora Cannabis (NYSE: ACB) as its top pick in the industry. Over the past couple of months, quite a few Wall Street investment banks have chimed in on ... | For example, the cannabis industry's biggest cheerleader, Cowen Group, is looking for $75 billion in global sales by 2030, up from $12.2 billion in 2018, and has named Aurora Cannabis (NYSE: ACB) as its top pick in the industry. Another day, another sell rating for this hated marijuana stock Of course, one of the four ... | For example, the cannabis industry's biggest cheerleader, Cowen Group, is looking for $75 billion in global sales by 2030, up from $12.2 billion in 2018, and has named Aurora Cannabis (NYSE: ACB) as its top pick in the industry. Another day, another sell rating for this hated marijuana stock Of course, one of the four ... | For example, the cannabis industry's biggest cheerleader, Cowen Group, is looking for $75 billion in global sales by 2030, up from $12.2 billion in 2018, and has named Aurora Cannabis (NYSE: ACB) as its top pick in the industry. Bank of America is rating the two largest pot stocks in the world by market cap, Canopy Gro... |
38487.0 | 2019-04-23 00:00:00 UTC | The Top-Producing Marijuana Stock Isn't a Buy. Here's Why. | ACB | https://www.nasdaq.com/articles/top-producing-marijuana-stock-isnt-buy-heres-why-2019-04-23 | nan | nan | You'd struggle to find an industry with more robust long-term growth potential than legal cannabis. Depending on your preferred source, the marijuana industry is capable of $50 billion to $75 billion in annual sales by the turn of the next decade, which would represent anywhere from 12.5% to 16.7% compound annual growt... | Investors fall head over heels for this top pot producer Among the dozens upon dozens of pot stocks that investors have to choose from, none is more popular than Aurora Cannabis (NYSE: ACB), especially with millennials. These external sales channels will be of the utmost importance to Aurora and help ensure that its ma... | Investors fall head over heels for this top pot producer Among the dozens upon dozens of pot stocks that investors have to choose from, none is more popular than Aurora Cannabis (NYSE: ACB), especially with millennials. Although management suggests that peak output will top 500,000 kilos, in my view, Aurora Cannabis sh... | Investors fall head over heels for this top pot producer Among the dozens upon dozens of pot stocks that investors have to choose from, none is more popular than Aurora Cannabis (NYSE: ACB), especially with millennials. Five reasons Aurora Cannabis shouldn't be on your buy list One of the top reasons Aurora doesn't fit... | Investors fall head over heels for this top pot producer Among the dozens upon dozens of pot stocks that investors have to choose from, none is more popular than Aurora Cannabis (NYSE: ACB), especially with millennials. Five reasons Aurora Cannabis shouldn't be on your buy list One of the top reasons Aurora doesn't fit... |
38488.0 | 2019-04-23 00:00:00 UTC | 2 Big Reasons Aurora Cannabis Stock Could Rise to New All-Time Highs | ACB | https://www.nasdaq.com/articles/2-big-reasons-aurora-cannabis-stock-could-rise-new-all-time-highs-2019-04-23 | nan | nan | Shares of Aurora Cannabis (NYSE: ACB) have been on a tear in 2019. The leading marijuana producer's stock is already up more than 80% so far this year -- and a staggering 2,000% over the past three years.
But the marijuana industry's torrid expansion is still in its early innings, and plenty more gains could still lie... | Shares of Aurora Cannabis (NYSE: ACB) have been on a tear in 2019. Hemp-fueled gains In addition to marijuana, hemp is a massive potential market that should help to fuel Aurora Cannabis' growth in the years ahead. "Our goal is to strengthen our CBD-from-hemp supply chain as well as our hemp business of hemp-based supe... | Shares of Aurora Cannabis (NYSE: ACB) have been on a tear in 2019. Peltz has extensive contacts in the consumer goods industry, after having served on the board of powerful companies such as Mondelez International. An investment from a major consumer goods company on the order of Constellation Brands' $4 billion invest... | Shares of Aurora Cannabis (NYSE: ACB) have been on a tear in 2019. An investment from a major consumer goods company on the order of Constellation Brands' $4 billion investment in Canopy Growth or Altria's $1.8 billion deal with Cronos Group would require Aurora to sell a sizable stake in its business, but it could mak... | Shares of Aurora Cannabis (NYSE: ACB) have been on a tear in 2019. A partnership with a major beverage company, such as PepsiCo, could also accelerate Aurora's entry into the cannabis-infused drink market. Hemp-fueled gains In addition to marijuana, hemp is a massive potential market that should help to fuel Aurora Can... |
38489.0 | 2019-04-22 00:00:00 UTC | This Is Why Canopy Growth Is the Best Pot Stock | ACB | https://www.nasdaq.com/articles/why-canopy-growth-best-pot-stock-2019-04-22 | nan | nan | Ever since the cannabis craze hit Wall Street back in mid-2018, I’ve been pounding on the table saying that the best marijuana stock to buy in the group is Canopy Growth (NYSE:). The logic is simple: In addition to being the biggest player in the industry, CGC stock has long had one thing that no other cannabis company... | As of this writing, Luke Lango was long CGC and ACB. Ever since the cannabis craze hit Wall Street back in mid-2018, I’ve been pounding on the table saying that the best marijuana stock to buy in the group is Canopy Growth (NYSE:). The logic is simple: In addition to being the biggest player in the industry, CGC stock ... | As of this writing, Luke Lango was long CGC and ACB. Canopy struck a deal with major U.S. cannabis operator Acreage to buy that company for $3.4 billion once cannabis is legalized nationwide in the U.S. For those who don’t follow this industry closely, that’s a big deal. Roughly speaking, that single catalyst turned th... | As of this writing, Luke Lango was long CGC and ACB. Canopy struck a deal with major U.S. cannabis operator Acreage to buy that company for $3.4 billion once cannabis is legalized nationwide in the U.S. For those who don’t follow this industry closely, that’s a big deal. That is, as soon as cannabis is fully legal acro... | As of this writing, Luke Lango was long CGC and ACB. The big question is whether or not Canadian cannabis giants like Canopy will be able to capitalize on the big U.S. opportunity when it comes knocking. Canopy Growth Stock Has Long-Term Upside My long-term bull thesis on Canopy Growth stock is that, if this company ca... |
38490.0 | 2019-04-22 00:00:00 UTC | This Pot Stock Is a Surprising Top Pick From Bank of America | ACB | https://www.nasdaq.com/articles/pot-stock-surprising-top-pick-bank-america-2019-04-22 | nan | nan | The secret is out: Cannabis is a big-dollar industry. Now that the legal pot industry has grown at a rapid pace for much of the decade, Wall Street investment firms are projecting massive annual sales figures for the end of the next decade. Cowen Group, arguably the industry's biggest cheerleader, believes yearly sales... | Two of these ratings went to the most popular pot stocks on the planet: Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB). Its joint venture with Molson Coors Brewing, known as Truss, will have nonalcoholic cannabis-infused beverages hitting dispensary shelves by this coming fall. Mind you, this rating was best... | Two of these ratings went to the most popular pot stocks on the planet: Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB). Bank of America initiates coverage on marijuana stocks Last week, Bank of America (NYSE: BAC) threw its hat into the ring and initiated coverage on four marijuana stocks, three of which rec... | Two of these ratings went to the most popular pot stocks on the planet: Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB). Bank of America initiates coverage on marijuana stocks Last week, Bank of America (NYSE: BAC) threw its hat into the ring and initiated coverage on four marijuana stocks, three of which rec... | Two of these ratings went to the most popular pot stocks on the planet: Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB). But as should surprise no one, Wall Street has been very indecisive regarding which pot stocks are the best to own to take advantage of this growth. Why HEXO? |
38491.0 | 2019-04-22 00:00:00 UTC | Why These Are the Top 2 Pot Stocks to Buy Right Now | ACB | https://www.nasdaq.com/articles/why-these-are-top-2-pot-stocks-buy-right-now-2019-04-22 | nan | nan | One of the big themes in the cannabis sector in 2019 has been increased Wall Street coverage. Specifically, Wall Street firms were largely unwilling to cover cannabis stocks in 2018 given the industry’s relative newness, rampant investor speculation and lack of fundamental tangibility. But, things have changed for mari... | In other words, the broad consensus among Wall Street firms is that when it comes to the cannabis space, investors should buy CGC and ACB, and forget about CRON and TLRY for the time being. According to TipRanks data, 10 analysts cover , while eight analysts cover ACB stock. Of those 18 ratings between CGC and ACB, non... | According to TipRanks data, 10 analysts cover , while eight analysts cover ACB stock. Of those 18 ratings between CGC and ACB, none of them are Sell ratings. Instead, the consensus rating on CGC stock is “Moderate Buy” while on ACB stock, it’s “Strong Buy.” Meanwhile, a third of the nine analysts who cover CRON stock h... | Instead, the consensus rating on CGC stock is “Moderate Buy” while on ACB stock, it’s “Strong Buy.” Meanwhile, a third of the nine analysts who cover CRON stock have a “Sell” rating on the shares. According to TipRanks data, 10 analysts cover , while eight analysts cover ACB stock. Of those 18 ratings between CGC and A... | Why Buy ACB Stock? According to TipRanks data, 10 analysts cover , while eight analysts cover ACB stock. Of those 18 ratings between CGC and ACB, none of them are Sell ratings. |
38492.0 | 2019-04-21 00:00:00 UTC | 5 Marijuana Stocks With the Most Debt: Should Investors Be Worried? | ACB | https://www.nasdaq.com/articles/5-marijuana-stocks-most-debt-should-investors-be-worried-2019-04-21 | nan | nan | Debt simply hasn't been a major issue for many companies in the marijuana industry. There's a simple reason for that: Banks wouldn't loan them any money.
But it's becoming easier for marijuana businesses to obtain loans. And some companies with core businesses outside of the cannabis industry have taken on debt to mak... | And some companies with core businesses outside of the cannabis industry have taken on debt to make acquisitions to jump on board the marijuana bandwagon. But Scotts began taking on more debt several years ago to acquire suppliers to the U.S. cannabis industry. One analyst has already cut revenue estimates for Canopy G... | The biggest debtors The five companies that operate in the marijuana industry with the highest total long-term debt levels right now are: Data sources: YCharts; company regulatory filings and press releases. Aurora Cannabis has the highest debt level of this group adding the company's issuing of $345 million of convert... | The biggest debtors The five companies that operate in the marijuana industry with the highest total long-term debt levels right now are: Data sources: YCharts; company regulatory filings and press releases. Aurora Cannabis has the highest debt level of this group adding the company's issuing of $345 million of convert... | Which marijuana stocks have the most debt? Investors probably don't need to worry too much just yet about Aurora, Tilray, and Aphria, though. Aphria thinks it's possible that revenue will reach 500 million Canadian dollars (around US$375 million) this year and double that amount in 2020. |
38493.0 | 2019-04-20 00:00:00 UTC | Marijuana Stocks: Let the Writedowns Begin | ACB | https://www.nasdaq.com/articles/marijuana-stocks-let-writedowns-begin-2019-04-20 | nan | nan | The cannabis industry has been on fire since the new year began, and it's not hard to understand why. The passage of the Cannabis Act in Canada last year allowed recreational weed to be legalized for the first time in an industrialized country, paving the way for marijuana and marijuana stocks to step out of the shadow... | For example, Aurora Cannabis (NYSE: ACB) might be the most popular pot stock of them all, at least among millennials, but it's lugging around a dangerous amount of goodwill and intangible assets. That might sound fantastic, but with sequential kilograms sold actually falling from the second quarter, the bulk of the sal... | For example, Aurora Cannabis (NYSE: ACB) might be the most popular pot stock of them all, at least among millennials, but it's lugging around a dangerous amount of goodwill and intangible assets. Aphria ended the quarter with CA$674.4 million in goodwill out of CA$2.05 billion in total assets, and its balance sheet is ... | For example, Aurora Cannabis (NYSE: ACB) might be the most popular pot stock of them all, at least among millennials, but it's lugging around a dangerous amount of goodwill and intangible assets. The end result in the third quarter, mostly as a result of this writedown, was a net loss of CA$108.2 million, or CA$0.43 pe... | For example, Aurora Cannabis (NYSE: ACB) might be the most popular pot stock of them all, at least among millennials, but it's lugging around a dangerous amount of goodwill and intangible assets. The end result in the third quarter, mostly as a result of this writedown, was a net loss of CA$108.2 million, or CA$0.43 pe... |
38494.0 | 2019-04-19 00:00:00 UTC | 16 Marijuana 4/20 Facts That Show How Far the Cannabis Movement Has Come | ACB | https://www.nasdaq.com/articles/16-marijuana-420-facts-show-how-far-cannabis-movement-has-come-2019-04-19 | nan | nan | For most of my life, marijuana has been considered a taboo topic that wasn't discussed openly and was swept under the rug by federal, state, and local officials. It was understood that a black market existed, but the "war on drugs" was always in force, with marijuana placed side by side with heroin and cocaine as scour... | This includes the largest pot stock in the world by market cap, Canopy Growth (NYSE: CGC), as well as Aurora Cannabis (NYSE: ACB), the projected leader in peak annual pot production in Canada. But as we near 4/20, a date of significance within the cannabis community that's celebrated by smoking or consuming marijuana, ... | This includes the largest pot stock in the world by market cap, Canopy Growth (NYSE: CGC), as well as Aurora Cannabis (NYSE: ACB), the projected leader in peak annual pot production in Canada. The U.S. Food and Drug Administration has approved a cannabis-derived drug Federal and state governments aren't the only one's ... | This includes the largest pot stock in the world by market cap, Canopy Growth (NYSE: CGC), as well as Aurora Cannabis (NYSE: ACB), the projected leader in peak annual pot production in Canada. Pot stocks are being listed side by side with time-tested businesses Marijuana stocks have long been listed on the over-the-cou... | This includes the largest pot stock in the world by market cap, Canopy Growth (NYSE: CGC), as well as Aurora Cannabis (NYSE: ACB), the projected leader in peak annual pot production in Canada. Canada's passage of the Cannabis Act last year allowed it to become the first industrialized country in the world to allow peop... |
38495.0 | 2019-04-18 00:00:00 UTC | If You Can Tolerate Risk, Hexo Stock Is a Buy | ACB | https://www.nasdaq.com/articles/if-you-can-tolerate-risk-hexo-stock-buy-2019-04-18 | nan | nan | Ah, the magic of analyst ratings! After a tough month in April, cannabis firm Hexo (NYSEAmerican:) suddenly reversed course after Bank of America analyst Christopher Carey initiated coverage. Sizing up the risk and reward profile, Carey assigned a “buy” rating on Hexo stock with a $10 price target.
Source: Shutterstock... | After a tough month in April, cannabis firm Hexo (NYSEAmerican:) suddenly reversed course after Bank of America analyst Christopher Carey initiated coverage. Sizing up the risk and reward profile, Carey assigned a “buy” rating on Hexo stock with a $10 price target. Finally, Carey mentioned “value-add partnerships” that... | Primarily, HEXO stock is undervalued relative to its peers. Next, the BofA analyst mentioned that Hexo stock is levered toward a “de-risked” Canadian cannabis market. Upgrade Suggests Rising Credibility for Cannabis Stocks Indeed, Hexo’s Molson partnership has advantages over an expected synergy like Cronos Group (NASD... | Underappreciated Elements Support Hexo Stock The best way I can characterize Hexo stock is as a diamond in the rough. Next, the BofA analyst mentioned that Hexo stock is levered toward a “de-risked” Canadian cannabis market. Upgrade Suggests Rising Credibility for Cannabis Stocks Indeed, Hexo’s Molson partnership has a... | Of course, in the marijuana sector, “undervalued” is an extremely relative term. Next, the BofA analyst mentioned that Hexo stock is levered toward a “de-risked” Canadian cannabis market. And major conservative figures have more or less voiced support for full legalization. |
38496.0 | 2019-04-18 00:00:00 UTC | Why Aurora Cannabis Is Issuing So Much Stock and Debt | ACB | https://www.nasdaq.com/articles/why-aurora-cannabis-issuing-so-much-stock-and-debt-2019-04-18 | nan | nan | Aurora Cannabis (NYSE:) is having a busy year raising its cash on hand. It filed a $750 million mixed shelf offering at the start of the month. In mid-January, it filed a $250 million aggregate principal amount of convertible senior notes due 2024. What is the company doing with all this money? And if markets continued... | Executive Chairman Michael Singer : “Although we have no immediate intention of drawing capital against this Shelf Prospectus, we have introduced this option as a prudent and long-term strategic measure to provide us with flexibility in access to growth capital, if or when required, to continue executing on our global ... | Executive Chairman Michael Singer : “Although we have no immediate intention of drawing capital against this Shelf Prospectus, we have introduced this option as a prudent and long-term strategic measure to provide us with flexibility in access to growth capital, if or when required, to continue executing on our global ... | Executive Chairman Michael Singer : “Although we have no immediate intention of drawing capital against this Shelf Prospectus, we have introduced this option as a prudent and long-term strategic measure to provide us with flexibility in access to growth capital, if or when required, to continue executing on our global ... | Executive Chairman Michael Singer : “Although we have no immediate intention of drawing capital against this Shelf Prospectus, we have introduced this option as a prudent and long-term strategic measure to provide us with flexibility in access to growth capital, if or when required, to continue executing on our global ... |
38497.0 | 2019-04-18 00:00:00 UTC | These 15 Pot Stocks Will Generate the Highest Sales in 2020 | ACB | https://www.nasdaq.com/articles/these-15-pot-stocks-will-generate-highest-sales-2020-2019-04-18 | nan | nan | Last year was transformational for the marijuana industry, with Canada becoming the first industrialized country in the world to legalize recreational weed, a handful of U.S. states green-lighting cannabis in some capacity, and multiple pot stocks moving from the over-the-counter exchange to either the New York Stock E... | Aurora Cannabis (NYSE: ACB): $642.8 million Aphria (NYSE: APHA): $627.8 million Canopy Growth (NYSE: CGC): $594.5 million Acreage Holdings: $525.1 million MedMen Enterprises: $470.3 million GW Pharmaceuticals: $429.8 million Tilray: $373.1 million The Green Organic Dutchman: $327.6 million Charlotte's Web Holdings: $31... | Aurora Cannabis (NYSE: ACB): $642.8 million Aphria (NYSE: APHA): $627.8 million Canopy Growth (NYSE: CGC): $594.5 million Acreage Holdings: $525.1 million MedMen Enterprises: $470.3 million GW Pharmaceuticals: $429.8 million Tilray: $373.1 million The Green Organic Dutchman: $327.6 million Charlotte's Web Holdings: $31... | Aurora Cannabis (NYSE: ACB): $642.8 million Aphria (NYSE: APHA): $627.8 million Canopy Growth (NYSE: CGC): $594.5 million Acreage Holdings: $525.1 million MedMen Enterprises: $470.3 million GW Pharmaceuticals: $429.8 million Tilray: $373.1 million The Green Organic Dutchman: $327.6 million Charlotte's Web Holdings: $31... | Aurora Cannabis (NYSE: ACB): $642.8 million Aphria (NYSE: APHA): $627.8 million Canopy Growth (NYSE: CGC): $594.5 million Acreage Holdings: $525.1 million MedMen Enterprises: $470.3 million GW Pharmaceuticals: $429.8 million Tilray: $373.1 million The Green Organic Dutchman: $327.6 million Charlotte's Web Holdings: $31... |
38498.0 | 2019-04-18 00:00:00 UTC | If You Can Tolerate Risk, Hexo Stock Is a Buy | ACB | https://www.nasdaq.com/articles/if-you-can-tolerate-risk-hexo-stock-is-a-buy-2019-04-18 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Ah, the magic of analyst ratings! After a tough month in April, cannabis firm Hexo (NYSEAmerican: HEXO ) suddenly reversed course after Bank of America analyst Christopher Carey initiated coverage . Sizing up the risk and reward profile, Carey assigned a "b... | As such, I mentioned earlier that I liked Hexo stock, even compared to relative heavyweight Aurora Cannabis (NYSE: ACB ). Sizing up the risk and reward profile, Carey assigned a "buy" rating on Hexo stock with a $10 price target. Finally, Carey mentioned "value-add partnerships" that go beyond the scope of Hexo's exist... | As such, I mentioned earlier that I liked Hexo stock, even compared to relative heavyweight Aurora Cannabis (NYSE: ACB ). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ah, the magic of analyst ratings! Next, the BofA analyst mentioned that Hexo stock is levered toward a "de-risked" Canadian cannabis ma... | As such, I mentioned earlier that I liked Hexo stock, even compared to relative heavyweight Aurora Cannabis (NYSE: ACB ). 7 Stocks to Buy for Spring Season Growth Of course, by the time that you're reading this, this dramatic burst in Hexo stock is in the past. Underappreciated Elements Support Hexo Stock The best way ... | As such, I mentioned earlier that I liked Hexo stock, even compared to relative heavyweight Aurora Cannabis (NYSE: ACB ). Of course, in the marijuana sector, "undervalued" is an extremely relative term. Next, the BofA analyst mentioned that Hexo stock is levered toward a "de-risked" Canadian cannabis market. |
38499.0 | 2019-04-17 00:00:00 UTC | Is CGC Stock on the Right Track? | ACB | https://www.nasdaq.com/articles/cgc-stock-right-track-2019-04-17 | nan | nan | Canopy Growth (NYSE ), along with most other cannabis firms, continues to operate at a loss as it builds out the infrastructure, develops its markets and develops goods that differentiate itself from the competition. Yet so far, pot stock investor seem oblivious to the risks of ongoing losses for the foreseeable future... | Even if it reaches full utilization on time, investors are hardly assured that revenue from sales will exceed the costs for producing edibles and beverages. Temporarily non-producing facilities, absorption of the medical excise tax and commitments to sales and marketing and corporate infrastructure spending led to an a... | Source: Shutterstock Operational Efficiency Canopy Growth’s yield potential in Canada is a good indicator of the company’s operational efficiency. The company continues to believe that its medical opportunity globally over the next three years has a higher growth potential over the recreational market. As the legalizat... | Canopy Growth (NYSE ), along with most other cannabis firms, continues to operate at a loss as it builds out the infrastructure, develops its markets and develops goods that differentiate itself from the competition. Source: Shutterstock Operational Efficiency Canopy Growth’s yield potential in Canada is a good indicat... | Medical Platform The medical side of Canopy Growth faced some pressure in the third quarter. By looking at Canopy’s $4.9 in cash, most of which came from Constellation Brands, Inc. (NYSE: ), investors are at least assured that the company will not run out of money any time soon. The Bottom Line on CGC Stock The risks i... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.